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Abstract
The response of bacteria to environmental stresses including antibiotic stresses is
one of the key factors helping them survive and evolve. In this thesis, we stud-
ied antibiotic resistance in two different aspects: mutagenic effect of antibiotics and
mechanisms of antibiotic resistance. In many bacteria, including Escherichia coli,
the stimulation of mutagenesis is mediated by the SOS response. Thus, blockage or
attenuation of this response through the inhibition of RecA has been proposed as a
possible therapeutic adjuvant in combined therapy to reduce the generation of antibi-
otic resistance. We studied the capacity of sublethal concentrations of antimicrobials
of different families with different molecular targets, which cause the increase in the
mutant frequency of E. coli, and the effects that the inactivation of recA would have
on the antibiotic-mediated mutagenesis. We tested the mutagenicity of 13 antibi-
otics; among them eight antibiotics stimulate E. coli mutagenesis (slightly in most
cases), with trimethoprim alone or in combination with sulfamethoxazole producing
the highest impacts. Inactivation of recA abolishes the mutagenic effect and also pro-
duces increased susceptibility to some anti-microbials. The fact that inactivation of
recA reduces mutagenicity and/or increases the activity of a large number of antimi-
crobials, supports the hypothesis that RecA inhibition might have favourable effects
on antibiotic therapy. We also studied the responses of bacteria under the antibi-
otic pressure including the development of antibiotic resistance. Thus, a library of
11.000 Mycobacterium smegmatis insertion mutants were constructed and analyzed
to find candidates which may have a rifampicin resistant phenotype. Rifampin is
an important first-line antibiotic for the treatment of tuberculosis. Although most
rifampin-resistant strains arise through mutations in the rpoB gene in mycobacteria,
a proportion of such strains showed no rpoB mutations. This suggests that alternative
mechanisms are responsible for rifampin resistance. We found that the disruption of
trkA, a putative regulator of K+ uptake, and the disruption of ich, a putative K+
channel lead to increased rifampicin resistance. Our data indicate that TrkA and Ich
are important for maintenance of the M. smegmatis growth rate, its pH homeosta-
sis and membrane potential. Besides increasing rifampicin resistance, inactivation of
these genes confers resistance to other hydrophobic agents, such as novobiocin, as
well as increased susceptibility to isoniazid and positively charged aminoglycosides.
We suggest that trkA and ich are general regulators of antibiotic susceptibility, and
that changes in the multidrug susceptibility/resistance pattern detected in the trkA
and ich mutants are associated with the membrane hyperpolarization.
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Resume´n
La respuesta de las bacterias frente el estre´s ambiental, incluyendo el estre´s generado
por los antibio´ticos, es uno de los factores clave que las ayuda a sobrevivir y evolu-
cionar. En esta tesis, hemos estudiado la resistencia a antibio´ticos desde dos puntos de
vista distintos: El efecto mutage´nico de los antibio´ticos y los mecanismos de resisten-
cia a los mismos. En muchas bacterias el incremento de la mutage´nesis esta´ mediada
por la respuesta SOS. Por lo tanto, se ha propuesto el bloqueo o atenuacio´n de dicha
respuesta mediante la inhibicio´n de RecA como tratamiento adyuvante en terapias
combinadas para reducir la aparicio´n de resistencia a los antibio´ticos. Nosotros hemos
estudiado la capacidad de concentraciones subletales de antimicrobianos de diferentes
familias con distintas dianas moleculares que causan un incremento en la frecuencia de
mutantes en E. coli y los efectos que una inactivacio´n de recA tienen en la mutage´nesis
mediada por antibio´ticos. Exploramos la mutagenicidad de trece antibio´ticos, de los
cuales ocho estimulan la mutage´nesis en E. coli (ligeramente en la mayor parte de los
casos), siendo el Trimetropin por s´ı solo o en combinacio´n con Sulfametoxazol, el que
produce mayor efecto. La inactivacio´n de recA elimina el efecto mutage´nico y adema´s
incrementa la sensibilidad a ciertos antimicrobianos. El hecho de que la inactivacio´n
de recA reduce la mutagenicidad y/o aumenta la actividad de un gran nu´mero de
antimicrobianos apoya la hipo´tesis de que la inhibicio´n de RecA podr´ıa tener efectos
favorables en la terapia antibio´tica.
Tambie´n se ha estudiado la respuesta bacteriana en frente a la presio´n ejercida
por antibio´ticos, incluyendo el desarrollo de resistencia. De esta manera, se con-
struyo´ una librer´ıa de 11.000 mutantes por insercio´n de Mycobacterium smegmatis,
los cuales se analizaron en busca del fenotipo resistente a rifampicina. La rifampicina
es uno de los antibio´ticos de primera linea utilizado para el tratamiento de tubercu-
losis. Si bien la resistencia a rifampicina en mycobacteria esta´ principalmente dada
por mutaciones en rpoB, hubo fenotipos resistentes a rifampicina que no presentaron
mutaciones en dicho gen. Esto sugiere que existen mecanismos alternativas respon-
sables de de la resistencia a rifampicina. Durante el trabajo, hemos observado que
la disrupcio´n del gen trkA, un regulador putativo de la introduccio´n de potasio a la
ce´lula, as´ı como la disrupcio´n de ich, un canal de potasio putativo, incrementan la
resistencia a rifampicina. Nuestros resultados indican que tanto TrkA como Ich, son
importantes para mantener la el equilibrio a´cido-base, tasa de crecimiento y potencial
de membrana en M. smegmatis. Adema´s de aumentar la resistencia a rifampicina,
la inactivacio´n de estos genes confiere resistencia a otros agentes antimicrobianos de
tipo hidrofo´bico como la novobiocina, as´ı como tambie´n provoca un aumento en la
sensibilidad a isoniazida y a antibio´ticos aminoglico´sidos cargados positivamente. A
partir de los resultados obtenidos, sugerimos que trkA y ich regulan de manera general
la suceptibilidad a antibio´ticos, y que los cambios en los perfiles de susceptibilidad
y resistencia a mu´ltiples antibio´ticos observados en las mutantes de trkA e ich se
asocian a la hiperpolarizacio´n de la membrana.
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1.1 Antibiotic stress and the development of an-
tibiotic resistance
Like the other living organisms, bacteria are continuously exposed to environmental
stresses and are able to adapt themselves to severe fluctuations of the environment.
There are many factors causing stresses in bacteria. Among them, the presence of
antibiotics produces different types of vital stresses. Studying the evolution of the
bacterial cell structure under such stressful conditions is an important research topic
because it provides us with an insight of how bacteria become antibiotic resistant.
Antibiotics can provoke antibiotic resistance through mutator selection. Simple or
successive selections with antibiotics for mutant phenotypes increase the proportion of
mutator strains in a cell population [Mao et al., 1997]. In such cases, antibiotics used
for selections do not only stimulate resistance to themselves, but also the increase of
mutator strains may result in acquired resistance of a selected population to other an-
tibiotics. Bacteria acquire resistance to antibiotics by one of two mechanisms: either
spontaneous mutations or horizontal transfer. Resistance by spontaneous mutations
depends on the mutation rate and the presence of proofreading and repair mecha-
nisms [Miller, 1996]. Mutations may cause the resistance of bacteria to antibiotics by
modifying their target, by changing their uptake or by stimulating an increase of their
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eﬄux [Hooper, 2001, Normark and Normark, 2002]. This kind of resistance is usually
found in bacteria that do not have any effective mechanisms of gene transferring such
as Mycobacterium tuberculosis. On the other hand, resistance by horizontal transfer
of genes is the main mechanism of acquired resistance. A horizontal gene trans-
fer usually consists of three different basic processes: conjugation, transduction and
transformation [Rice, 2000]. These processes do not only occur in the same species
but also among different ones. Thus, horizontal transfers are a major reason of wide
spreading resistance [Salyers and Ama´bile-Cuevas, 1997, Maiden, 1998].
Mutations and horizontal transfers can occur together. Indeed, in the resis-
tance caused by genes such as extended-spectrum TEM-type β-lactamase variants,
the horizontal transfer introduces new resistant alleles in a cell population. Then
these alleles are modified to produce various variants of resistance by mutations
[Blazquez et al., 1995, Blazquez et al., 2000].
1.2 Bacterial models used in this work
Escherichia coli : is Gram-negative, rod-shaped, flagellated, motile, oxidase neg-
ative and facultative anaerobe. It is a member of the Enterobacteriaceae family
[Buxton and Fraser, 1977] usually having two types of metabolism: respiratory and
fermentative, which commonly take place in the intestinal tract of humans and other
animals. In 1922, E. coli K-12 strain was isolated [Bachmann, 1972]. This strain does
not have virulence characteristics; it grows easily in laboratory media. Moreover, it
has been proven to be an useful model for microbial physiology and genetic research.
In one part of this thesis, we examined the role of antibiotics as mutagens in E.coli .
Mycobacterium smegmatis, used as a model organism in this study, is a Gram-
positive bacterium with high G+C DNA which belongs to the genus Mycobacterium,
the Mycobacteriaceae family, the Corynebacterineae suborder, the Actinomycetales
order and the Actinobacteridae class. Species in the genus Mycobacterium consist of
both environmental nonpathogenic organisms and obligate, opportunistic pathogenic.
Mycobacteria have an unusual structure because their cell wall contains a complex of
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long chains of mycolic acids and peptidoglican-arabinogalactan.
In particular, mycobacteria are usually classified to either slow or fast-growing
groups. M. smegmatis being aerobic belongs to the latter one. Besides, M. smegma-
tis is considered as a saprophytic and non-pathogenic microorganism although it may
cause skin and soft-tissue lesions [Brown-Elliott and Wallace, 2002]. Unlike most of
pathogenic mycobacterial species, M. smegmatis is a simple model and is easy to
work with because of its fast growing rate and requiring cheaper infrastructures for
experiments. There are many similarities between M. smegmatis and the much more
virulent obligate mycobacterial pathogens such as Mycobacterium tuberculosis. They
both have the same unusual cell wall structure and have 90% genetic homology to
each other [Tyagi and Sharma, 2002]. In addition to the aforementioned properties,
the M. smegmatis mc2 155 strain is hyper-transformable; it is an efficient host for
the eclectroporation of DNA [Snapper et al., 1990] and is now the work-horse of my-
cobacterial genetics. Furthermore, it is readily cultivatable in most of synthetic or
complicated laboratory media, where it can form visible colonies in quite a short time
from just three to five days. For these reasons, M. smegmatis became more popular
in scientific laboratories than M. tuberculosis or any other mycobacterial pathogens.
1.3 Antibiotics stimulate mutagenesis in E. coli
1.3.1 The SOS system
The SOS system is a cellular response to DNA damage; it is a programmed DNA
repair which results in DNA mutagenesis and genetic exchange or recombination
[Matic et al., 1995]. The SOS system is a regulon consisting of over 40 unlinked
genes [Radman, 1975]. Two key regulatory proteins LexA and RecA are involved
in the regulation and the induction of SOS response [Miura and Tomizawa, 1968,
Defais et al., 1971]. LexA is a transcriptional repressor that has two typical domains:
an N-terminal DNA-binding and a C-terminal dimerization and catalytic domain
[Luo et al., 2001, Schnarr et al., 1988, Oertel-Buchheit et al., 1993]. The LexA pro-
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tein binds to a site in the promoters of the SOS genes (SOS box) and down-regulates
the expression of these SOS genes, including the lexA gene [Courcelle et al., 2001,
Fernandez De Henestrosa et al., 2000]. RecA is an inducer protein of SOS response;
it plays an important role in homologous recombination and in many DNA repair
pathways such as repairing daughter strand gaps, double strand breaks and SOS mu-
tagenesis. RecA is activated by binding itself to a single-stranded DNA (ssDNA) pro-
duced by DNA damages during the replication processes and forming a nucleoprotein
filament in the presence of ATP [Chen et al., 2008, Cox, 2007]. The activated form
of RecA , usually known as ReA*, interacts with LexA and activates the self-cleavage
activity of LexA (also known as auto-cleavage) leading to the dissociation of LexA
from the SOS boxes. It results in the induction of the SOS regulon [Little et al., 1980].
When a DNA damage is repaired, the activity of RecA* disappears, thus, functional
LexA is re-accumulated and binds to the operator region of the SOS genes, and finally
the expression of SOS genes is prevented [Erill et al., 2007].
When the SOS response is induced by DNA damage, multiple genes involved in
repair, replication, recombination and cell division are expressed. Among them some
important genes are listed below:
1. In nucleotide excision repair (NER): uvrD (helicase encoding UvrD), uvrA and
uvrC encode subunits UvrA and UvrC of the UvrABC nuclease. The NER
repairs any damage caused by ultraviolet radiation.
2. In replication: polB, dinB and umuD, C encode the polymerases II, IV and
V respectively. These enzymes are able to bypass DNA lesions blocking chain
elongation by the DNA polymerase III.
3. In recombination:
• recA: encodes the RecA protein, which also have a role in SOS regulation
system and is one of the key proteins involved the homologous recombina-
tion process.
• recN : encodes the RecN protein involved in recombination via the RecFOR
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pathway.
• ruvAB : encodes the RuvA and RuvB proteins, being responsible for the
resolution of the holiday junctions created during homologous recombina-
tion.
4. In cell division:
• sulA encodes the SulA protein, which inhibits cell division by interact-
ing with the FtsZ protein being responsible for cell septation process
[Trusca et al., 1998].
• ftsK : encodes a DNA translocase that coordinates the processes of chro-
mosome segregation and cell division [Liu et al., 1998].
1.3.2 The SOS mutagenesis
The first action of SOS response is rescuing cells via restarting replications. SOS
mutagenesis is an error-prone DNA replication process allowing the bypass of DNA
lesions induced by UV or other external agents via a special kind of DNA repair
machinery [Walker, 1985]. Under usual conditions, the amount of LexA in a cell is
enough to control the expression of the SOS genes and lexA itself. When auto-cleavage
of LexA occurs via RecA* action, several genes from the SOS regulon are expressed
to activate error-prone DNA replication and the damage is therefore repaired. When
the reparation is finished, the concentration of LexA increases and the expression of
the SOS genes is again inhibited. During the SOS response, three main repairing
processes occur: excision, recombination and mutagenic repair.
The genes encoding DNA polymerases II (encoded by polB), IV (encoded by dinB)
and V (a product of umuD, C genes) are expressed through the induction of SOS
response. These genes known as error-prone DNA polymerases are responsible for
continuing of DNA replication with DNA lesions that cannot be replicated by DNA
polymerase III. This kind of replication is called translesion DNA synthesis. However,
these polymerases have low fidelity on replication, thus, errors can be introduced
during this process causing the generation of mutations [Sutton et al., 2000].
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1.3.3 Antibiotics increase mutagenesis via the induction of
SOS responses
It has been demonstrated that some antibiotics increase the mutagenesis via their
ability to induce the SOS response in bacteria [Ysern et al., 1990]. Among them,
quinolones work as good inducers of the SOS system. They are DNA-damaging
antibiotics which can increase mutant frequency via the induction of RecA-mediated
processes including also the induction of the error-prone DNA-polymerase expression
[Kohanski et al., 2010]. Quinolones induce the SOS response by a mechanism in which
the RecBCD nuclease/helicase is required [Newmark et al., 2005]. These drugs target
DNA gyrase and form a drug-stabilized gyrase cleavage complex to inhibit the DNA
replication. RecBCD processes the conversion of drug-stabilized cleavage complex
into DNA breaks. This process produces ssDNA which is necessary to activate RecA
to form RecA* that is required for the induction of the SOS response.
Other antibiotics being able to induce the SOS response are β-lactams. These
antibiotics are cell wall synthesis inhibitors, their targets in bacteria are penicillin
binding proteins (PBPs) which play an important role in the synthesis of peptido-
glycan. The PBP3 protein encoded by ftsI, is a key element in the septation during
cell division [Ishino and Matsuhashi, 1981] and is a target of β-lactams including
ceftazidime. It has been demonstrated that inhibition of PBP3 by β-lactams stim-
ulates the SOS response in E. coli [Miller et al., 2004] and the transcription of the
dinB gene encoding the error-prone DNA polymerase IV [Perez-Capilla et al., 2005].
Moreover, it also has been shown that the cephalosporin ceftazidime elicits adap-
tive responses, including the increase of mutant frequency in Pseudomonas aerugi-
nosa [Blazquez et al., 2006]. In addition, it is known that sub-inhibitory concentra-
tions of the fluoroquinolone antibiotic ciprofloxacin promote genetic recombination
in E. coli [Lopez and Blazquez, 2009, Lopez et al., 2007]. Recently, Kohanski et al.
[Kohanski et al., 2010] have demonstrated that sublethal levels of some bactericidal
antibiotics induce mutagenesis and this induction correlates with an increase in reac-
tive oxygen species (ROS), which in turn produces an induction of the SOS response.
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1.4 Anti-Tuberculosis drug resistance problem
The discovery of antibiotics is one of the most important breakthroughs in mod-
ern medicine. Since then, antibiotics have been widely used for effectively treating
and avoiding many popular bacterial infections in both human and animal bodies.
However, bacteria evolve very quickly to adapt themselves to new environments and
become resistant to many popular antibiotics. The recent fast increase of antibiotic
resistance causes a number of issues in health care. Nowadays, many well-known
antibiotics quickly become ineffective making treatment processes more complicated
and expensive. So far, some studies show that the main reason of antibiotic resistance
is inappropriate use of antibiotics. It is shown that over-use and misuse of antibiotics
can lead to the appearance and the wide-spread of antibiotic resistance.
Tuberculosis (TB) is a disease caused by several strains of mycobacteria, mainly
by M. tuberculosis. From the beginning, anti-TB drugs have been very effective in
protecting patients from tuberculosis. However, there might be unexpected side-
effects of inappropriate using anti-TB drugs. On one hand, they kill bacteria but on
the other hand they stimulate bacteria to become resistant to those drugs. Resistance
to anti-TB drugs happens during the selection of drug-resistant mycobacteria with
spontaneous mutations. When a treatment regimen is inadequate these resistant
mutants widely spread and replace wild type strains. Drug resistance developing
when there is no history of a TB treatment is called resistance among new cases
or primary drug resistance. Similarly, drug resistance developing during or after
the courses of a treatment is defined as resistance among previous treated cases or
acquired drug resistance.
The wide spread of TB resistance to many locations supposses a huge challenge
for many TB control programs. The increase of TB resistance is usually due to many
factors including the neglects of governments in TB control, inadequate accesses and
infrastructures, economic circumstances, poor managements of TB control programs,
population growth, migrations and a rising number of TB cases in HIV infected
individuals. Studies on drug resistance in many locations showed that the number
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of drug resistant TB is much higher in developing countries than developed countries
[Espinal, 2003].
Initially, bacteria are only resistant to a specific drug. However, as time goes by
they accumulate mutations being resistant to every individual drug. Finally, they may
become multi-drug resistance (MDR) [Ramaswamy et al., 2000]. In the literature
[Iseman, 1999], MDR-TB is usually defined as TB organisms that are resistant to
isoniazid and rifampicin whose are the two most potential first-line anti-tuberculosis
drugs. Patients with MDR-TB are difficult to be treated effectively because it requires
long-term treatments with more toxic, expensive and effective drugs. Besides, there
is a high possibility that they can remain as source of infection for a long period.
Another type of TB resistance is XDR-TB defined as TB with resistance to at least
isoniazid and rifampicin and resistance to a fluroquinolone or a second line injectable
agent (i.e. amikacin, kanamycin or capreomycin)[for Disease Control and Prevention, 2010].
This kind of resistance is identified as among the group of dangerous resistance which
results in very poor outcome and high mortality rate [Raviglione and Smith, 2007].
Both MDR-TB and XDR-TB strains are resistant to the most of important anti-TB
drugs. These kinds of resistance make TB control programs more complicated.
1.5 The burden of disease caused by TB
Statistics data regarding the magnitude of the TB epidemic all over the world reported
by the World Health Organization shows that one third of the world’s population is
infected by M. tuberculosis. In 2010, there were 8.8 million new infection cases; 1.1
million of deaths caused by TB infections from HIV-negative people and an additional
number of 0.35 million of deaths from HIV-associated TB. The majority of new cases
occurred in Asia (55%), followed by Africa (30%), the Eastern Mediterranea (7%),
Europa (5%) and America (3%).
According to a report of WHO, “There are about 5% of previously treated or new
TB patients being identified as MDR-TB infections in most countries. An estimation
of 16% of 290 thousands of cases of MDR-TB may exist among notified TB patients
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in 2010” [WHO, 2011]. The highest rates of the MDR-TB among new cases were
discovered in former Soviet Union states and China, where a high percentage of
patients fail to respond to standard drug therapy.
TB is the leading killer of HIV-infected individuals. In fact, it was estimated about
13% of TB infection cases reported among people living with HIV [WHO, 2011]. The
rate of TB in areas with high HIV prevalence such as in Africa is much more than the
rate of TB in low HIV prevalence areas. In developing countries, TB mainly affects
young people who are the major economic labors of the society. Another serious fact
is that TB is the main cause of death among women, especially in Africa. In 2010,
there are 3.2 million women being identified as incident cases of TB, among them
there are 0.32 million deaths [WHO, 2011].
1.6 The mechanisms of antibiotic resistance in my-
cobacteria
M. tuberculosis does not contain plasmid; they can develop resistance to antibiotic
via accumulation of spontaneous chromosomal mutations. In general, resistance of
mycobacteria to antibiotics can be classified as either intrinsic (natural) or acquired
(chromosomal mutations). Resistance is usually provided by four different mecha-
nisms:
1. modification of permeability of the cell wall
2. the activation of eﬄux pump system
3. drug degradations or modifications
4. drug target modifications
In particular, acquired drug resistance is mainly characterized by mutations in chro-
mosomal genes, producing the selection of resistant strains during drug therapy.
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1.6.1 Mycobacterial cell wall acts as a barrier against antibi-
otic penetration
Like the other free living bacteria, mycobacteria are covered by a cell wall. The cell
wall not only keeps mycobacteria’s shape but also protects them from harmful factors
such as different osmotic pressure and physical or chemical compounds. Nevertheless,
the chemical compositions of the cell wall and the assembly of the different macro-
molecules that make it up are modified during the growth and morphogenesis of cells.
Mycobacteria have a special and complex cell wall with significantly low permeability.
This characteristic serves as one of the major reasons of antibiotic resistance.
More than 60 % of the mycobacterial cell wall correspond to lipids. The structure
of mycobacterial cell envelope usually consists of two lipid layers. The first one is
a regular inner membrane, while second one is a layer mainly comprising of long-
chain mycolic acids whose are covalently linked to peptidoglycan via arabinogalactan
network (mAGP) [Minnikin, 1982]. When components of the cell wall are extracted,
under the action of different detergents, beside soluble components such as proteins
and free lipids, the mAGP complex remains insoluble.
Mycolic acids are long chains α-alkyl β-hydroxyl fatty acids, usually containing
from 60 to 90 carbon atoms. They are strongly hydrophobic molecules forming the
inner leaflet of the lipid bilayer of the cell wall. Lipoarabiomannan (LAM) and lipo-
mannan (LM) are also forming the cell wall [Minnikin, 1982]. Mycolic acid layers are
believed to have responsibility for the low permeability of mycobacteria. It works as
the outer membrane of Gram-negative organisms and prevents the entry of hydrophilic
compounds as antibiotics [Jarlier and Nikaido, 1994, Brennan and Nikaido, 1995]. How-
ever, mycobacteria cell wall is about a thousand times less permeable than Gram-
negative bacteria such as E. coli.
It has been demonstrated that mycolic acid layers play an important role in form-
ing an effective barrier against antibiotics. Liu and Nikaido [Liu and Nikaido, 1999]
showed that the mycolate-deficient mutant failed to synthesize full-length mycolic
acids and it increases susceptibility to hydrophobic compounds such as novobiocin,
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rifampicin, erythromycin and crystal violet. The increase of the permeability was
considered as one of the possible reasons for the increase of susceptibility to various
hydrophobic compounds.
There are two different systems for biosyntheses of short chain and long chain
fatty acids in mycobacteria. Indeed, the short chain fatty acids are synthesized by the
fatty acid synthase I complex (FASI), while the long chain fatty acids are synthesized
by the extension of the mercomycolate precursors from FASI by the FASII complex
[Barry et al., 1998]. Cole et al. [Cole et al., 1998] showed that genes encoding FASII
enzymes in M. tuberculosis are located in two loci: an operon having four genes:
fabD-acpM-kasA-kasB and another mabA-inhA operon. These enzymes were tested
as potential drug targets for TB.
The cell wall usually contains free lipids which are not covalently linked to peptidoglican-
arabinogalactan such as asglycopeptidolipids or phthiocerol-dimycocerosates (DIMs/PDIMs)
or the sulfolipids or the cord factor and so on [Minnikin, 1982]. These lipids have been
shown to be important in maintaining an outer membrane like the structure of my-
cobacteria.
Free lipids play an important role in forming an effective barrier against antibiotics
in M. tuberculosis. DIMs/PDIMs are produced by M. tuberculosis and a few other
mycobacteria or most pathogenic in humans and animals. They are the main lipids of
tubercle bacillus and play a role in the cell wall permeability [Camacho et al., 2001].
Many studies have implicated these molecules in the virulence of M. tuberculosis. Hy-
drophobic compounds can pass through the cell wall directly via the lipid membrane.
Meanwhile the penetration of hydrophilic solutes is very low; they can diffuse via pore
proteins-porins in the mycobacterial cell wall.
The porin of M. chelonae is the first one reported in mycobacteria. When the cell
wall of M. chelonae is extracted by detergents, it is found to contain proteoliposomes,
i.e. a channel-forming activity destroyed by protease. Subsequently, this channel-
forming activity is purified and finally, it becomes a 59 kDa cell wall protein that
allows the small and hydrophilic solutes to enter the cell [Trias et al., 1992]. The
purified protein contains negative charges at its mouth and produces action-selective
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channels. Nevertheless, unlike enterobacterial porin, the M. chelonae porin is a minor
protein of the cell wall. Its amount is less than the amount of porin found in E.coli.
Besides, it produces far lower permeability than that produced by the porin of E. coli
[Trias et al., 1992]. These observations can be considered as an explanation of why
the permeability of the M. chelonae cell wall to hydrophilic solutes is quite low.
In M. tuberculosis there is a molecule known as OmpATb which may play an
important role in permeability to small hydrophilic solutes. OmpATb is a pore-
forming protein and it appears to function as a porin. The OmpATb is required for
adaptation of M. tuberculosis at low pH. The mutants of M. tuberculosis lacking of the
ompA gene did not change their profile of antibiotics resistance [Raynaud et al., 2002]
and up to now there have not been any evidence showing the participation of OmpA
in the uptake of antibiotics.
MspA is the main porin of M. smegmatis and is responsible for the uptake of
hydrophilic solutes. In M. smegmatis, there is a set of very similar porins known
as Msp A, B, C and D. In wild type M. smegmatis, there are only expressions
of mspA and mspC. When the mspA gene is deleted, the transcription of mspB
and mspD is activated [Stephan et al., 2005]. It has been shown by Stephan et al.
[Stephan et al., 2004] that porin pathway across the cell wall plays an important
role in the sensitivity of both hydrophobic and hydrophilic antibiotics of M. smeg-
matis. MspA plays a major role in uptake of β-lactam antibiotics, moreover, the
small and hydrophilic antibiotics such as, fluoroquinolones and norfloxacinalso cross
the cell wall via Msp porin pathway. Other hydrophobic antibiotics such as chlo-
ramphenicol, erythromycin, novobiocin and rifampicin use porins to enter the cell as
well [Danilchanka et al., 2008]. Mutants of M. smegmatis with a defected mspA gene
increased resistance to the first line antibiotics such as rifampicin, ethambutol and
isoniazid at high concentration as well as the second line antibiotics such as fluoro-
quinolones and cycloserine at concentration close to the MICs. It can also become
multi-drug resistance [Stephan et al., 2004].
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1.6.2 Eﬄux pump systems
Eﬄux pumps are one of the reasons of low-level intrinsic resistance in bacteria. The
concentration of drug inside the cell depends on the balance of its influx and ef-
flux [Viveiros et al., 2003]. Drug eﬄux pumps in bacteria were classified in several
main families including the major facilitator superfamily (MFS), multidrug and toxic
compounds extrusion (MATE), resistance-nodulation cell division (RND), small mul-
tidrug resistance (SMR) and the ATP binding cassette (ABC) [Li and Nikaido, 2004,
Saier et al., 1998].
In mycobacteria, MFS, RND, SMR and ABC eﬄux pumps were known to involve
in drug resistance. In the following subsections, we enumerate several mycobacterial
drug eﬄux pumps which have been carefully studied.
MFS eﬄux pumps
Analysis of M. tuberculosis genome with bioinformatic tools helped identify 16 puta-
tive MFS eﬄux pumps [De Rossi et al., 2002]. However, not all of them were com-
pletely understood in their roles in drug resistance. M. smegmatis LfrA, was the
first multidrug eﬄux pump reported in mycobacteria by [Takiff et al., 1996]. Over-
expression of the lfrA gene confers resistance to fluoroquinones, acriflavine and other
toxic compounds such as ethidiumbromide [Li et al., 2004, Sander et al., 2000]. The
lfrR, i.e. an upstream of the lfrA gene, encodes a TetR-like regulator in which the lfrR
gene acts as a repressor of lfrA. The deletion of the lfrR gene leads to strong expression
of lfrA and causes the increase of high resistance to cationic dyes, fluoroquinolones and
tetracycline. It also induces slightly resistance to INH [Li et al., 2004]. There is no
homology of lfrA in M. tuberculosis, suggesting that there may be other eﬄux pumps
contributed to the resistance of this mycobacterium to fluoroquinolones. Indeed, the
Rv1634 eﬄux pump in M. tuberculosis confers resistance to various fluoroquinolones
when it is over-expressed in M. smegmatis [De Rossi et al., 2002].
The Tet(V) is an eﬄux pump isolated from M. smegmatis. The increase of tetra-
cycline MIC was observed when Tet(V) is over-expressed in M. smegmatis. However,
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the analysis of the Tet(V) distribution showed that only M. smegmatis and M. for-
tuitum have this eﬄux pump [De Rossi et al., 1998a]. Other MFS eﬄux pumps were
also identified in mycobacteria such as Tap and P55. Tap is an eﬄux pump of M.
fortuitium and has a homology Rv1258c in M. tuberculosis and causes the resistance
to aminoglicosides and tetracycline [Ainsa et al., 1998]. Moreover, the correlation be-
tween the transcription level of Rv1258c and drug resistance was determined in clinical
M. tuberculosis isolates resistant to rifampicin and ofloxacin [Siddiqi et al., 2004]. The
increase level of Rv1258c transcripts was observed when the isolates were grown in
the presence of rifampicin and ofloxacin. However, both of these antibiotics were not
shown to be substrates of Tap [Ainsa et al., 1998]. This suggests that eﬄux pumps
may be stimulated in response to the presence of the corresponding drugs.
The P55 eﬄux pump in M. bovis and its M. tuberculosis homologue, known as
Rv1410c, ia also associated with low-level resistance to aminoglycosides and tetra-
cycline [Silva et al., 2001]. Recently, it has been shown that mutants lacking of P55
in M. bovis BCG increased susceptibility to various toxic compounds including ri-
fampicin and clofazimine [Ramon-Garcia et al., 2009].
The epfA gene encodes a putative eﬄux pump EpfA in M. tuberculosis H37Rv.
The secondary structure of this eﬄux pump is similar to that of members of trans-
porter family QacA. To the best of our knowledge the association between EpfA and
drug resistance in M. tuberculosis has not been well understood yet. Nevertheless,
the deletion of epfA homologue in M. smegmatis causes an increase of susceptibility
to ethidium bromide, gentamicin, FQ and acriflavine [De Rossi et al., 2006].
SMR family drug transporters
Mmr encoded by the mmr gene is a member of the SMR family, which was identified
in M. tuberculosis. Other mmr -like genes exist in other Mycobacterium species includ-
ing: M. simiae, M. gordonae, M. marinum, M. smegmatis and M. bovis [De Rossi et al., 1998b].
The expression of the mmr gene in M. tuberculosis or in M. smegmatis results in re-
sistance to tetraphenyl phosphonium, ethidiumbromide, erythromycin, safranin O
and pyronin Y [De Rossi et al., 1998b]. Moreover, mutants with the deletion of the
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mmr homologue in M. smegmatis increase susceptibility to cationic dyes and flouro-
quinolones.
RND drug transporters
The genome sequence of M. tuberculosis consists of 13 putative transporters predicted
to belong to RND family [Cole et al., 1998]. The MmpL (mycobacterial membrane
proteins, large) appears to be confined to mycobacteria [Pasca et al., 2005]; they share
sequence and structure similarities to each other. The mmpL7 gene of M. tuberculosis
confers high level resistance to INH (MIC is 32 times higher than wild type) when
it is over expressed in M. smegmatis. This fact indicates that the MmpL7 protein
actively pumps out INH in M. smegmatis [Pasca et al., 2005].
ABC drug transporters
There are at least 37 ABC transporters completely and incompletely identified in M.
tuberculosis [Braibant et al., 2000]. Only a few of them has been characterized and
determined to play a role in drug resistance in M. tuberculosis. The genome sequenc-
ing and analyzing of M. tuberculosis show that M. tuberculosis has the doxorubicin-
resistance operon, i.e. drrAB [Cole et al., 1998]. The expression of the drrAB genes
in M. smegmatis confers resistance to antibiotics such as tetracycline, erythromycin,
ethambutol, norfloxacin, streptomycin and chloramphenicol. This resistant pheno-
type can be reversed by treatments with verapamil or reserpine which are known as
eﬄux pump inhibitors [Choudhuri et al., 2002].
Phosphate specific transporter (Pst) has been reported in many bacteria including
M. tuberculosis. The high level of transcription [Banerjee et al., 1998] and chromoso-
mal amplification [Banerjee et al., 2000] of the pstB gene encoding PstB was observed
in the M. smegmatis ciprofloxacin resistant mutant generated in a laboratory. The
active eﬄux pump plays a major role in resistance to ciprofloxacin of this strain
[Bhatt et al., 2000]. An ABC transporter encoded by the Rv2686c-Rv2687c-Rv2688c
operon of M. tuberculosis plays an important role in fluoroquinolones eﬄux when it
is produced from a multi-copy plasmid. Over-expression of this operon in M. smeg-
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matis confers resistance to ciprofloxacin and norfloxacin. Pump inhibitors reserpine,
verapamil and carbonyl cyanide m-chlorophenylhidrazole (CCCP) reduce the level of
resistance [Pasca et al., 2004].
1.6.3 Drug tolerance
The tolerance of M. tuberculosis to several commonly used antibiotics limits the
chemotherapy. In many cases, it is considered as the root of TB treatment fail-
ure. Morris et al. [Morris et al., 2005] described a mycobacterial system inter-
connecting with resistance to antibiotics penetrating the cell wall; it enables my-
cobacteria to tolerate to antibiotics which inhibit cytoplasmic targets. This sys-
tem depends on whiB7 which is a gene encoding a WhiB7 transcriptional regulator.
WhiB7 belongs to a family of regulator proteins WhiB which is restricted to the
Actinomycetes [Soliveri et al., 2000]. In Steptomyces coelicolor there are 14 genes
belonging to the whiB family, among them whiB7 plays a role in multidrug re-
sistance phenotype. The replacement of whiB7 in M. tuberculosis, M. bovis BCG
or in M. smegmatis (Nguyen et al., unpublished manuscript) causes the sensitivity
to variety of antibiotics including macrolides, a lincosamide, and an aminoglycoside
[Morris et al., 2005, Nguyen and Thompson, 2006].
Moreover, the expression of whiB7 is significantly induced by minimal inhibi-
tion concentration of erythromycin, tetracycline and high concentration of strep-
tomycin. It also controls the expression of a regulon that contains at least eight
genetic loci including two well documented antibiotic resistant genes tap and erm
[Morris et al., 2005]. Similar to the other WhiB proteins, WhiB7 seems to work to-
gether with the primary sigma factor (SigA) in control of its regulon. Nevertheless,
genome of M. tuberculosis encodes 12 alternative sigma factors, among them there is
SigF being antibiotic-inducible and taking part in intrinsic multidrug resistance.
The iniBAC operon is strongly induced when M. bovis BCG or M. tuberculosis
are treated with ethambutol or INH. This operon confers multidrug tolerance via
an associated pump-like activity [Colangeli et al., 2005]. Over-expression of the M.
tuberculosis iniAgene in the M. bovis BCG under exposure to either INH or etham-
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butol may result in tolerance to these antibiotics. M. tuberculosis mutants with iniA
deletion increase susceptibility to INH [Colangeli et al., 2005].
Lsr2 is a small histone-like protein with broad down-regulatory and up-regulatory
activities in M. smegmatis. In M. tuberculosis it controls the iniBAC operon and the
other antibiotic-induced genes including the efpA gene. This protein regulates genes
by modifying the DNA shape; it introduces a small number of coils into the DNA
structure. Therefore, Lsr2 is broadly considered as one of the major regulators of
antibiotic-induced responses in mycobacteria [Colangeli et al., 2007].
1.6.4 Molecular mechanisms of resistance to the first and the
second line anti-TB drugs
Isoniazid
Isoniazid (INH) is one of the first-line antibiotics in the treatments of tuberculosis.
It was first reported as anti-tuberculosis in 1952. Isoniazid has a very simple struc-
ture consisting of a pyridine ring and a hydrazide group. These two components are
believed to have an essential role in the high activity against Mycobacterium tubercu-
losis.
Isoniazid enters the mycobacterial cell through passive diffusion [Bardou et al., 1998].
It is a prodrug which must be activated mainly by the mycobacterial catalase-peroxidase
enzyme KatG encoded by the katG gene [Zhang et al., 1992]). In accordance with
its peroxidase activity, KatG activates INH by peroxidation to produce intracellular
reactive INH species. It is known that INH inhibits the synthesis of both mycolic and
nucleic acids. However, the mechanisms behind these processes are still unclear and
required more deep investigations.
In the presence of NADH (NAD+ or NAD. radical) reactive INH intermediates lead
to the formation of INH-NAD adducts which are powerful inhibitors of InhA. InhA
is an enoyl acyl carrier protein reductase [Banerjee et al., 1994, Dessen et al., 1995]
known as an important enzyme involving in mycolic acid biosynthesis. Moreover,
INH reacts with NADP+ to form an INH-NADP abduct strongly inhibiting MabA,
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an NADPH dependent β-ketoacyl-ACP reductase which also plays an important role
in mycolic acid biosynthesis [Ducasse-Cabanot et al., 2004]. Thus, INH-NAD and
INH-NADP adducts can inhibit different steps of cell wall lipid synthesis via inacti-
vation of important enzymes of this process including InhA and MabA, Furthermore,
it has been shown that the INH-NADP adduct binds M. tuberculosis dihydrofolatere-
ductase (DHFR) and blocks DHFR activities [Argyrou et al., 2006]. DHFR is central
in nucleic acid biosynthesis to make the nucleotide pools, thus its inhibition leads
to the prevention of the nucleic acid synthesis. In addition to that, another enzyme
target of INH is a complex of an acyl carrier protein (AcpM) and a β-ketoacyl-ACP
synthase (KasA), an enzyme taking part in mycolic acid synthesis.
Mutations in katG are the main mechanisms of INH resistance. Indeed, mutants
in katG have high level resistance to INH [Winder, 1982]. About 50% of INH resistant
clinical isolates of M. tuberculosis have deletions or missense mutations in the katG
gene. The Ser315Thr mutation is reported as the most frequent mutation among
isoniazid resistant mutations. The enzyme KatG with Ser315Thr mutation losses
its ability to activate INH, but it still remains about 50% of its catalase-peroxidase
activity [Rouse et al., 1996].
Resistance to INH may also be the results of other mutations in the promoter
regions of the mabA-inhA operon which leads to over expression of InhA or mutations
in the inhA gene causing the decrease of the InhA affinity to the INH-NAD adducts
[Rozwarski et al., 1998, Banerjee et al., 1994]. These mutations usually confer low-
level resistance. INH resistant mycobacteria containing mutation in the inhA gene
may have mutation in katG, they confers high level of resistance [Heym et al., 1995].
In addition to the aforementioned mutations, the mutations in the genes kasA,
acpM in clinical isolates exhibit low-level resistance to INH [Zhang and Telenti, 2000].
However, the role of KasA mutation in resistance to INH is still unclear. The reason
is that similar mutations are also found in INH-susceptible strains;in the case of
resistance to INH, mutations were also determined in the katG or the inhA genes
[Lee et al., 1999, Piatek et al., 2000].
Mutations in the promoter region of ahpC, encoding an alkylhydroperosidereduc-
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tase, may be another reason of INH resistance. These mutations cause over expression
of the AhpC enzyme and do not confer high-level resistance. The INH resistant strains
with these kinds of mutants also possess katG mutations [Zhang and Telenti, 2000,
Ramaswamy and Musser, 1998, Sherman et al., 1996]. The over expression of AhpC
was observed as a compensation for the lack of catalase-peroxidase in these mycobac-
terial strains [Wilson et al., 1998].
In M. smegmatis, mutations in ndh reducing the activity of NADH dehydrogenase
cause resistance to INH and ethionamide [Miesel et al., 1998]. In M. tuberculosis,
INH resistant strains with mutations in ndh may also have mutations in other genes
such as inhA or katG.
Recently, down regulation of katG expression has been determined to have a rela-
tion with INH resistance. Three mutations in furA-katG intergenic region substitution
were found in INH resistant clinical isolates of M. tuberculosis. Mutations in this re-
gion decrease the katG expression, thus, confer resistance to INH [Ando et al., 2011].
Furthermore, mutations in the intergenic region of oxyR-aphC reduce the level of
expression of inhA and also have been associated with INH resistance. These muta-
tions have been reported in 4.8% to 24.2% of INH resistant M. tuberculosis isolates
[Dalla Costa et al., 2009].
In addition, [Sholto-Douglas-Vernon et al., 2005] showed that INH is activated
by the human N-Acetyl transferase (NAT2), as well as by the M. tuberculosis NAT
enzyme [Upton et al., 2001]. When both nat genes of M. tuberculosis and M. smeg-
matis were expressed in M. smegmatis, an increase of INH resistance was observed
[Payton et al., 1999]. Moreover, the deletion of nat in M. smegmatis causes the in-
creasing sensitivity to INH [Payton et al., 2001].
Rifampicin
Rifampicin (rifampin) is a bacterial antibiotic drug of the group rifamycin. Rifampicin
was discovered in 1963 and introduced for TB chemotherapy in 1971 as a major
addition to the treatments methods of tuberculosis and inactive meningitis, along
with isoniazid, ethambutol, pyrazinamide and streptomycin. Currently, rifampicin
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is one of the most important anti-TB drugs in the treatments of TB in short-term
chemotherapy [Mitchison, 1992].
According to [Cole, 1994, Rastogi and David, 1993], rifampicin inhibits bacteria
RNA-polymerase activity; it binds β-subunit of RNA-polymerase and forms a stable
drug-enzyme complex . Therefore, the transcription of RNA from DNA template is
prevented. One of the most important characteristics of rifampicin is its great activity
against actively growing and slow metabolizing (non-growing) bacilli. Recently, resis-
tance to rifampicin is increasing rapidly as a result of the widespread of inappropriate
antibiotic usage.
Resistant mutant do not form complex between enzyme and rifampicin. Most
M. tuberculosis rifampicin resistance strains arise because of mutations in the rpoB
gene, which encodes the RNA polymerase β-subunit [Wehrli et al., 1968]. It was esti-
mated that around 95% of rifampicin resistant M. tuberculosis strains had mutations
located in the 81-bp region of the rpoB gene (codons 507 to 533). This region is
also known as the rifampicin resistance-determining region (RRDR). In most of the
studies, the bacterial strains with high resistance levels tend to harbor mutations at
codons 526 and 531 (about 60% of all mutations). Besides, the other additional mu-
tations have been mapped to positions 511, 512, 513, 516, and 533. These mutations
do not correlate with the increasing levels of resistance [Cummings and Segal, 2004,
Morlock et al., 2000]. Rifampicin resistant tuberculosis is often observed in combina-
tion with resistance to the other drugs, leading to long-term treatments and remark-
ably worse chemo-therapeutic outcomes. About 90% of rifampicin resistant clinical
isolates are also isoniazid resistant, thus, rifampicin resistance is a positive indicator
of multi-drug or extensive-drug resistance.
However, rifampicin resistant strains of M. tuberculosis with no mutations in 81-
bp region of the rpoB gene have been reported [Ohno et al., 1996]. Furthermore,
most of rifampicin resistant clinical isolates of M. avium and M. intracellulare did
not have any mutations in the rpoB gene [Guerrero et al., 1994], in M. smegmatis,
rpoB mutations have not yet been identifiable [Hetherington et al., 1995]. These data
suggest that there are mechanisms of rifampicin resistance being not fully addressed
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in the literature. To the best of our knowledge, the permeation and transport of
antibiotics into mycobacteria are still not yet well understood. Although there are
only a few studies on this topic, rifampicin, i.e. a hydrophobic antibiotic, is believed
to enter the mycobacteria cell through direct diffusion across the mycobacterial cell
wall. Most part of natural resistance of mycobacteria to rifampicin can be attributed
to a permeability of lipid-rich through mycobacterial cell wall [Hui et al., 1977].
Pyrazinamide
Pyrazinamide is an important first line anti-TB drug; it was discovered in 1952
and was not used extensively in TB treatment until 1980s. Utilization of this drug
helps treatment duration to be reduced from 9-12 months to 6 months. The drug
is most active against TB at acid pH (pH < 6) [McDermott and Tompsett, 1954].
The activity of pyrazinamide increases under low oxygen or anaerobic conditions
[Wade and Zhang, 2004].
Pyrazinamide is a prodrug entering M. tuberculosis cells through passive diffusion.
It must be activated to have its active form, i.e. pyrazinoic acid by the pyrazinami-
dase/nicotinamidase enzyme (PZase) which is encoded by the pncA gene in M. tuber-
culosis [Scorpio and Zhang, 1996]. Acid pH condition stimulates the formation of the
protonated pyrazinoic acid which then crosses the membrane and causes increasing ac-
cumulation of pyrazinoic acid anions and protons in the cell [Zhang et al., 1999]. The
accumulation of protons is a reason of the disruption of membrane potential which is
a main contributor of the proton motive force. The disruption of membrane potential
leads to the inhibition of the membrane transport. These facts indicate that pyrazi-
noic acid points to the membrane energy metabolism [Zhang et al., 2003]. Pyrazinoic
acid and its n-propyl ester were thought to inhibit enzyme fatty acid synthesis Fas-I
[Zimhony et al., 2000], but its validity is still questioning [Boshoff et al., 2002].
According to [Scorpio and Zhang, 1996, Scorpio et al., 1997, Cheng et al., 2000]
mutations in pncA are the major mechanisms of pyrazinamide resistance. Indeed,
most of mutations occur in the pncA gene and in its putative promoter regions
[Scorpio et al., 1997, Jure´en et al., 2008]. These mutants results in the loss or reduc-
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ing activity of PZase [Scorpio et al., 1997]. Between 72-97% of pyrazinamide resistant
M. tuberculosis strains have mutations in pncA [Scorpio et al., 1997, Louw et al., 2006,
Portugal et al., 2004]. However, some resistant strains do not have mutations in
pncA. It has been suggested that pyrazinamide resistance may be provided by mu-
tations in an unknown pncA regulator gene. Furthermore, another type of sim-
ilar resistant strains without pncA mutations has low-level resistance and retains
PZase activity; the mechanisms of such pyrazinamide resistance remain unidentified
[Sreevatsan et al., 1997b].
Pyrazinamide is highly active against M. tuberculosis, but it has a little or no ac-
tivity against other mycobacteria such as M. bovis. The reason may be due the differ-
ence between the pncA genes in many species of mycobacteria [Sun and Zhang, 1999].
Scorpio et al. [Scorpio and Zhang, 1996] shows that strains of M. bovis are naturally
resistant to pyrazinamide and do not have PZase, these characteristics are used to
differentiate M. bovis from M. tuberculosis.
Ethambutol
Ethambutol is a first line drug that is usually used in combination with INH, ri-
fampicin, pyrazinamide and streptomycin to avoid the spread of drug resistance in
TB. It was first discovered in 1962 and up to date it has been using as a part of a
standard treatment regimen for TB. Ethambutol is active against growing bacilli and
almost has no effect on non-replicating bacilli. It intervenes in biosynthesis of cell
wall agabinogalactan [Takayama and Kilburn, 1989]. The target of ethambutol was
identified to be arabinosyl transferase encoded by embB, an enzyme taken part in the
synthesis of arabinogalactan, in M. tuberculosis and in M. bovis. In M. tuberculosis,
embB belongs to an operon together with embA and embC in the order embCAB.
They share more than 65% of amino acid identity with each other and are predicted
to encode transmembrane proteins [Telenti et al., 1997, Belanger et al., 1996].
Mutations in the embCAB operon, usually in embB and occasionally in embC,
are the main mechanisms of resistance to ethambutol [Telenti et al., 1997]. According
to [Sreevatsan et al., 1997a], most of ethambutol resistant isolates in M. tuberculosis
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have mutations in embB . Mutations in embB codon 306 happen most frequently in
up to 20% of ethambutol-susceptible isolates [Lee et al., 2004, Ahmad et al., 2007].
Some studies have suggested that embB306 mutations did not cause the classical
ethambutol resistance. Instead, they were found to be associated with resistance to
other antibiotics and to multidrug resistance [Hazbon et al., 2005, Shi et al., 2007,
Perdigao et al., 2009]. Analysis of individual mutations causing different amino acid
substitutions showed that mutations producing certain amino acid changes caused
ethambutol resistance, while other amino acid substitutions had little or no effect on
ethambutol resistance. Mutations at embB306 also appeared to be necessary, but
not sufficient, to produce high-level EMB resistance in the clinical strains. There-
fore, these mutations must contribute indirectly to high-level resistance, probably,
via interaction with mutations in other genes [Safi et al., 2008].
However, there is a proportion about 35% of ethambutol resistant strains observed
without mutations in embB. This number is significant suggesting that there may be
other unknown mechanisms of resistance to ethambutol [Alcaide et al., 1997].
Aminoglycosides: streptomycin, kanamycin, amikacin and capreomycin
Steptomycin was first isolated in 1943 and was the first antibiotic that could be
used for TB treatment. It is an alternative first line anti-TB drug recommended by
WHO [Cooksey et al., 1996]. Therefore, streptomycin is usually used in the treat-
ment regimen of TB in combination with four other drugs including INH, rifampicin,
pyrazinamide and ethambutol.
Streptomycin is an inhibitor of protein synthesis. Indeed, it binds to the 30S sub-
unit of ribosome, leading to misreading of mRNA during translation [Davies et al., 1965].
Streptomycin interacts with the 16S rRNA encoded by the rrs gene and S12 ribosomal
protein encoded by the rpsL gene [Finken et al., 1993]. Mutations in the rrs gene and
the rpsL gene are the major original causes of resistance to streptomycin. About 50%
of streptomycin resistant strains have mutation in the rpsL gene. Among them muta-
tions causing a change from Lys to Arg in codon 43 and 88 are the most common and
result in high-level of resistance. There are about 20% streptomycin resistant isolates
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harbor mutations in the rrs gene. These mutations were found mainly in the loops
of the 16S rRNA, in two regions around nucleotides 530 and 915 [Finken et al., 1993,
Nair et al., 1993]. However, low-level streptomycin resistant strains without muta-
tions in both of the rrs genes and the rpsL genes were reported. Hence, there might
be an alternative mechanism for streptomycin resistance [Cooksey et al., 1996]. Re-
cently, mutations in the gidB encoded a conserved 7-methylguanosine methyltrans-
ferase specifically for the 16S rRNA have been discovered as a main reason of low-level
resistance to streptomycin [Okamoto et al., 2007, Spies et al., 2008].
Kanamycin and amikacin also inhibit protein synthesis by modification of riboso-
mal structures at the 16S rRNA. High-level resistance to kanamycin and amikacin
is provided by mutations at codon 1400 of the rrs gene [Alangaden et al., 1998,
Suzuki et al., 1998].
Capreomycin is a peptide antibiotic. Mutations in the tlyA gene are associated
with resistance to capreomycin. This gene encodes an rRNA methyltransferase. The
activity of this enzyme is lost when mutations occur in the tlyA [Maus et al., 2005].
Cross-resistance maybe found between kanamycin, amikacin and capreomycin
[Winder, 1982]. The A1401G mutation in the rrs gene causes resistance to all the
three antibiotics. Mutant strains being resistant to kanamicin and capreomycin could
have C1402T or G1484T mutation in the rrs gene. Multiple mutations may also
happen in the rrs gene in one strain causing cross-resistance among these antibiotics
[Maus et al., 2005].
Fluoroquinolones
Fluoroquinolones are broad-spectrum antibiotics being very important in treatments
of serious bacterial infections. These antibiotics are currently used as second-line
drug in TB treatments. The targets of fluoroquinolones in most bacterial species
are DNA gyrase (topoisomerase II) and topoisomerase IV. DNA topoimesomerases
are responsible for maintaining chromosomes in an appropriate topological structure
[Drlica and Malik, 2003]. M. tuberculosis only have DNA gyrase which is a tetrameric
protein containing A and B subunits encoded by the gyrA and the gyrB genes re-
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spectively [Wang, 1996, Takiff et al., 1994]. Fluoroquinolone resistance is a result of
mutations in the putative fluoroquinolone binding to a region in gyrA or in gyrB. It is
a conserved region, i.e. the quinolone resistant determining region (QRDR) of gyrA
(320 pb) and gyrB (375 pb) which was determined to play the most important role in
resistance to fluoroquinolones [Takiff et al., 1994]. Among mutations in gyrA of M.
tuberculosis, the most frequently mutated positions were identified at codons 90 and
94. Nevertheless, other mutations at codons 74, 88 and 99 have also been reported
[Chen et al., 2004, Sun et al., 2008]. Mutation at codon 95 contains a polymorphism
and it is not involved in quinolone resistance [Sreevatsan et al., 1997a]. Mutations in
gyrB seem to be very rare.
There are other mechanisms of fluoroquinolone resistance. The contribution of
eﬄux pumps in resistance to these antibiotics was mentioned in the eﬄux pump part
of this thesis. Recently, resistance to quinolones mediated by MfpA was determined.
MfpA is a member of the pentapeptide repeat family of proteins from M. tuberculosis.
Its expression causes resistance to ciprofloxacin and sparfloxacin. This protein binds
to DNA gyrase and inhibits its activity. The MfpA with three-dimensional structure
contains a fold named as the right-handed quadrilateral -helix, which displays size,
shape and electrostatic similarity to B-form DNA. It was suggested that MfpA com-
petes with B-from DNA for the gyrase surface. MfpA binding to DNA-gyrase forbids
the formation of DNA gyrase-DNA complex which is the target of fluoroquinolonee.
Therefore it prevents the lethal interaction of the drugs with DNA gyrase and provides
a molecular explanation for the antibiotic resistance mechanism [Hegde et al., 2005].
In addition, the mutations in the gyr genes confer high-level resistance to fluoro-
quinolones, while the alternative mechanisms usually relate to low-level of resistance
[Chen et al., 2004]. However, the combination of gyr mutations and alternative mech-
anisms results in a considerable level of resistance to fluoroquinolones.
Ethionamide
Ethionamide is an important drug usually used for treatments of MDR-TB. Similar to
isoniazid, ethionamide is a prodrug that needs to be activated by a mono-oxygenase
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EthA encoded by the ethA genes [DeBarber et al., 2000]. EthA is a flavin adeno-
sine dinucleotide. It activates ethionamide through oxidation to active intermediates
which subsequently form adducts with NAD. The ethionamide-NAD adduct inhibits
the same target as the INH, particularly, the InhA of the mycolic acid synthesis
pathway [Banerjee et al., 1994].
Mutations in the ethA gene and the inhA gene result in the resistance to ethion-
amide [Hazbon et al., 2006]. Moreover, mutations in inhA may alter the InhA target
or mutations in the promoter region of inhA causing the over-expression of inhA and
confer cross-resistance to ethionamide and isoniazid [Vilcheze et al., 2006]. In addi-
tion to that, cross-resistance to these drugs is also a result of mutation in ndh which
increases the intracellular concentration of NADH [Vilcheze et al., 2005].
Moreover, the expression of ethA is negatively regulated by the ethR gene encod-
ing of the EthR protein [Baulard et al., 2000, DeBarber et al., 2000]. EthR belongs
to the TetR/CamR family of transcriptional regulators; it binds to the ethA operator,
5 to 16 nucleotides upstream from the ethA gene start codon [Aramaki et al., 1995,
Engohang-Ndong et al., 2004]. The over expression of the ethR genes causes repres-
sion of ethA expression, thus, it results in ethionamide resistance [Baulard et al., 2000,




In this thesis, we studied mutagenesis effect of antibiotics and mechanisms of antibi-
otic resistance of bacteria. Two model organisms were used: Escherichia coli and
Mycobaterium smegmatis.
2.1 Mutagenic effect of antibiotics in E. coli
Low concentrations of some antibiotics have been reported to stimulate mutagenesis
and recombination, whose may facilitate adaptation of bacteria to different types
of stresses, including antibiotic pressure. However, the mutagenic effects of most
of the currently used antibiotics remains untested. In this part, we would like to
study the roles of antibiotics in the stimulation of mutagenesis of E. coli via SOS
response. Indeed the effect of recA inactivation on mutagenesis was studied under
the treatments of variety antibiotics with different concentrations around their MIC.
In order to achieve the aforementioned goals our studies are planned as follows:
• To study the mutagenic effect of difference antibiotics on the E. coli E12 strains
by evaluating mutant frequency of bacteria in rifampicin and fosfomycin resis-
tance.
• To study the effect of antibiotics on the induction of recA transcription
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• To study the effect of antibiotics on mutant frequency in the mutant lacking of
the recA gene.
• To study the effect of antibiotics on cell morphology.
2.2 Antibiotic resistance in M. smegmatis
Antibiotic resistances in mycobacteria is one of the most emergency issues in the
world. In this thesis, we would like to analyze the possible resistant mechanisms in
the model organism M. smegmatis. It has been well-known that mutation in rpoB is
one of the main mechanisms of rifampicin resistance. However, there are alternative
mechanisms of rifampicin resistant which are not provided by mutations in rpoB.
Therefore, in this study we aim at characterizing those mechanisms in M. smegmatis.
The plan of our study is as follows:
• To generate an insertion mutant library of M. smegmatis by tranposon muta-
genesis using φMycoMarT7.
• to screen the mutant library for mutants that may be resistant to rifampicin.
• To characterize the rifampicin resistant candidates with disruptions in the trkA
and ich genes, focusing in the following characteristics:
– Antibiotic resistant profile
– Growth properties under different conditions including at normal condi-
tions and at acidic pH conditions




3.1 Bacterial strains and plasmids
Bacterial strains used in this thesis are: Mycobacterium smegmatis wild-type strain
mc2 155. The Escherichia coli K-12 strains used were: MG1655 (F−, lambda−,
rph-1, wild-type K-12 strain) ME12 (MG1655 lacZDC-lacZDN-yfp) and an ME12
recA :: kan derivative (ME12 recA938::Tn5 (KnR)). Escherichia coli DH5α (F−,
endA1, hsdR17 (r−, m+), supE44, thi1, recA1, gyrA, relA1, D( lacZYA, argF)U169,
80 [D lacZM15]).
Plasmids are listed in the following table:
Plasmid Description Source or reference
p2NIL Gene manipulation vector, KnR [Parish and Stoker, 2000]
p2NIL-∆trkA p2NIL containing an in-frame deletion of the trkA gene This study
p2NIL-∆ich p2NIL containing an in-frame deletion of the ich gene This study
pGOAL19 HygR PAg85 -lacZ Phsp60 -sacBS PacI cassette vector, AmpR [Parish and Stoker, 2000]
pVV16 Mycobacteria expression vector with HygR, KnR and Phsp60 [Schulbach et al., 2001]
pvv16-trkA pvv16 containing the trkA gene This study
pvv16-ich pvv16 containing the ich gene This study
pSC101-PrecA::GFP GFP transcriptional fusion after the promoter [Ronen et al., 2002]
of the recA gene with KnR
Table 3.1: Plasmids
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3.2 Bacterial media and growth conditions
LB (Luria-Bertani) broth (USB Corporation): 20g was added to 1L purified water.
For LB agar 15g of agar was added to the liquid media and sterilized by autoclaving.
Difco Middlebrook 7H9 broth (BD biosciences): 4.7g was added to 900 ml purified
water and was sterilized by autoclaving, 100 ml Middlebrook ADC enrichment (BBL)
and 0.05% Tween80 was added before using.
Difco Middlebrook 7H10 agar (BD biosciences): 19g was added to 900 ml purified
water and sterilized by autoclaving, add 100ml Middlebrook ADC enrichment (BBL)
and 0.05% Tween80 was added before using.
Media supplements: all media supplements were obtained from Sigma. They are
listed with their stock concentrations as following: hygromycin B at 100 mg/ml,
kanamycin at 50 mg/ml, 5-bromo-4chloro-3-indolyl-b-D-galactoside (X-gal) at 20
mg/ml in DMSO, sucrose at 40mM.
M. smegmatis wild-type strain mc2 155 and its mutant derivatives were grown
at 37oC in Middlebrook 7H9 broth or Middlebrook 7H10 agar. For strain selection,
media were supplemented with 25 µg/ml kanamycin or 50 µg/ml hygromycin B or 40
mg/ml XGAL or 10 mM sucrose, when necessary. E. coli DH5a strain was cultured
at 37oC in LB medium containing 50 µg/ml kanamycin or 100 µg/ml hygromycin,
when appropriate.
Long-term storage of bacterial strains was carried out by adding 0.2 ml of 80%
v/v sterile glycerol to 1 ml aliquots of an overnight culture and stored at -80oC.
3.3 General techniques of bacterial genetics
The methods for preparation of competent or electro-competent cells, transformation
by heat-shock or electroporation, transduction with phage and so on follow the in-
struction of the techniques described in the literature by Sambrook [Sambrook et al., 1989],
Miller [Miller, 1992], Parish and Brown [Parish and Brown, 2011].
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3.4 DNA techniques
All of the techniques such as restriction digestion of DNA, ligation of DNA fragments,
agarose gel electrophoresis and isolation of M. smegmatis genomic DNA were designed
based on the protocols proposed by Sambrook [Sambrook et al., 1989] and Parish and
Brown [Parish and Brown, 2011]. Besides, the plasmids of E.coli were purified using
the Qiagen QiAprep Spin Miniprep kit.
The specific amplification of DNA regions was done using the polymerase chain
reaction. PCR reactions were performed in 50µL volumes containing 1.25U AmpliTaq
Gold DNA polymerase (Roche), 0.2mM each dNTP, 1.5mM of MgCl2, 0.5 µM each
primer, 20ng of DNA template and 1 x PCR buffer.
3.5 Colony PCR
The reaction was carried out in 50µL volumes and the same PCR cycle was also
maintained. The colony of E.coli was re-suspended in the PCR mix and the PCR per-
formed on it. In the case of colony PCR of M. smegmatis, the colony was re-suspended
in 50ml sterile water in an eppendorf. Later on, the mix was being incubated at 90oC
for 15 minutes before being centrifuged and adding 3µml of the supernatant to the
PCR mix as a template.
The purification of PCR products and restriction digests was carried out using
the Qiagen QiAquick PCR Purification Kit in accordance with the manufacturer’s
instructions. For the purification of DNA from an agarose gel slice the Qiagen Qi-
Aquick Gel Extraction kit was used.
3.6 DNA sequencing
The sequence of plasmids and PCR products were carried out by the sequencing ser-
vices of the company Secugen1 using the modified dideoxy-chain termination method.
The oligos used for reactions are shown in Table 3.2.
1http://www.secugen.es
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3.7 Oligos used in this study
All oligos were synthesized by Sigma-Aldrich and are listed in the following table
(underlined bases denote restriction sites):
Name Sequence (5’ 7→3’) Description
DeltrkA5’F CCCGCTGCAGGCCGTGTTGGCGGCCAGACA Fwd primer to amplify a fragment
up-stream of trkA from M. smegmatis
DeltrkA5’R GTCCAAGCTTTCGACCGCAGCGCG Rev primer to amplify a fragment
up-stream of trkA from M. smegmatis
DeltrkA3’F CCTCAAGCTTCCTGGATTCCGAATGAGCCG Fwd primer to amplify a fragment
down-stream of trkA from M. smegmatis
DeltrkA3’R GGTGGGTACCGACGACGCGGGCTGGCGCGA Rev primer to amplify a fragment
down-stream of trkA from M. smegmatis
Delich5’F GACAAAGCTTCGGCCACCGCGCGTGCGGTT Fwd primer to amplify a fragment
up-stream of ich from M. smegmatis
Delich5’R GCGAGGTACCATTCGAGTCGATGGCGGCCA Rev primer to amplify a fragment
up-stream of ich from M. smegmatis
Delich3’F GGCCGGTACCCGGCTCCTGTACATCCGCAG Fwd primer to amplify a fragment
down-stream of ich from M. smegmatis
Delich3’R CCAAGCGCGGCCGCCCTTATCCCGAGAAT Rev primer to amplify a fragment
GGGCCAC down-stream of ich from M. smegmatis
trkAF GGCCGCCATATGACCAGTCGGCGCGCTGCG Fwd primer to amplify trkA from
M. smegmatis
trkAR CCGCCTGCAGTCATTCGGAATCCAGGTCGT Rev primer to amplify trkA from
M. smegmatis
ichF GGATGACATATGGCTAAAGGCAGGTTACGG Fwd primer to amplify ich from
M. smegmatis
ichR CGGTAAGCTTTCATCGTTCGGCGTCCGCAC Rev primer to amplify ich from
M. smegmatis
MycoMar CCCGAAAAGTGCCACCTAAATTGTAAGCG Primer for sequencing to
specific primer identify the transposon insertion site
seqichF GGTGCGGTCATGGTTACATTG Fwd primer for sequencing checked the ich
knockout mutant
seqichR GACAGCAGCGGGACGTTAC Rev primer for sequencing checked the ich
knockout mutant
seqtrkA CATCCAGTCTATTAATTGTTGCCG Fwd primer for sequencing checked the
trkA knockout mutant




Mutant frequencies were obtained in the same way as described in the literature
[Lopez et al., 2007, Elez et al., 2007]. Briefly, for mutant frequency, 2 ml aliquots of
exponentially growing cells (108 cells/mL) were incubated with different concentra-
tions of antibiotic for 4 hours at 37oC with shaking (250 rpm). One ml of these
cultures was centrifuged for 10 minutes at 6000 rpm in a minifuge. The pellet was
resuspended in 2 ml of fresh LB medium and incubated overnight at 37oC with
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shaking. This step is necessary to resolve the filaments formed after treatments
with some antibiotics, such as ciprofloxacin, ceftazidime, trimethoprim and trimetho-
prim/sulfamethoxazole. Resolution of filaments was verified by direct observation
of samples from the different cultures under the microscope. Only cultures with a
proportion of filaments of less than 5% of total cells were plated. Viable cells were
determined by plating appropriate dilutions onto LB agar plates. Mutant frequen-
cies were obtained as the number of colonies growing on rifampicin (100 µg/ml) or
fosfomycin (10 µg/ml) plates per viable colony. At least three independent exper-
iments were performed for each antibiotic concentration, and three more, with five
replicas each, for the most mutagenic concentrations were performed. For the experi-
ments with the recA mutants, five independent experiments were performed for each
concentration.
3.9 Effects of antibiotics on recA expression
To qualitatively assess the antibiotic-mediated induction of transcription from the
recA promoter the strain ME12 containing the pSC101-PrecA::GFP reporter plasmid
was used. A 100 µl aliquot of an overnight culture was inoculated into LB soft
agar (0.7% agar) and spread onto LB plates. Antibiotic-containing filter discs were
deposited onto the agar and plates were visualized through a blue-light lamp after
24 hours of incubation at 37oC. Discs with mitomycin-C (10 mg), a known inducer
of the SOS system, or without antibiotic were used as a positive or negative control,
respectively.
3.10 Effects of antibiotics on cell morphology
The effect of low concentrations of antibiotics on cell morphology was studied by direct
observation of the treated cultures under an Olympus BX61 microscope. Aliquots (2
mL) of exponentially growing ME12 cells (108 cells/ml) were incubated with different
antibiotics for 4 hours at 37oC with shaking (250 rpm). After 4 hours of treatment,
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2 µl from each culture was used to prepare samples. These samples were scanned
and photographed under the microscope with an UplanF1 100 NA 1.30 oil immersion
objective.
3.11 Statistical analysis
Statistical evaluation was done by using the Mann-Whitney U-test when two groups
were compared. Differences were considered significant when P-values were less than
0.05.
MICs of antibiotics for ME12 and ME12recA were determined according to CLSI
recommendations (Clinical and Laboratory Standards Institute, 2008), except that
the bacterial inocula were identical to those used in all subsequent mutagenesis ex-
periments. Antibiotics tested for stimulation ofmutation were used at different con-
centrations around their MICs.
3.12 Generation and screening of M. smegmatis
ΦMycoMarT7 insertion library
Transposon ΦMycoMarT7, a mariner-based system, was used to obtain a M. smeg-
matis mutant library of random insertions. The isolation of a thermo-sensitive trans-
poson phage and preparation of high-titre phage stock have been described in the lit-
erature [Sassetti et al., 2003]. For transduction, M. smegmatis mc2 155 cultures were
washed with MP buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM MgSO4 and
2 mM CaCl2), mixed with the phage stock at a multiplicity of infection of 1:10 and
incubated (37oC, for 3 hours). Mycobacterial cells were then plated on Middlebrook
7H10 agar supplemented with kanamycin (25 µg/ml). The insertion mutants were
isolated as kanamycin-resistant colonies after 3 days of incubation at 37oC. Approx-
imately 11.000 clones were picked randomly and inoculated into individual wells in
96-well microtitre plates containing Middlebrook 7H9 medium.
To identify rifampicin-resistant mutants (M. smegmatis wildtype, MIC 2 µg/ml),
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each M. smegmatis transposition mutant was replicated onto Middlebrook 7H10 agar
plates supplemented with several rifampicin concentrations (5, 10 or 20 µg/ml).
Strains that showed resistance to the drug were retested twice to select only those
able to grow on rifampicin-containing plates. To confirm the resistance phenotype
for the selected mutants, the MIC of rifampicin was determined by the broth micro-
dilution method. In order to define antibiotic resistance, it has been proposed that
mycobacterial strains with a resistance ratio greater than 8 (defined as the MIC for
the test strain divided by the MIC for the wild-type strain) are considered as resistant
ones [Inderlied and Nash, 2005]. Thus, those mutants being able to grow on 20 µg/ml
rifampicin (equivalent to 10-fold the MIC of rifampicin for the parental strain) were
selected as candidates for further study.
3.13 Localization of ΦMycoMarT7 transposon in-
sertion site
To determine the insertion position of the transposon cassette in the M. smegma-
tis chromosome, purified genomic DNA from each resistant mutant was digested with
BamHI and religated with T4 ligase. Self-ligated plasmids contained the entire trans-
poson plus flanking chromosomal DNA next to the insertion site. Re-circularized
plasmids were electroporated into E. coli DH5αλpir116 and selected on LB with
kanamycin (50 µg/ml). After purification, plasmids were sequenced using a MycoMar-
specific primer that hybridizes next to the transposon/chromosome junction. The
DNA sequences adjacent to each insertion site were compared with the M. smegmatis
genome sequence to identify the interrupted gene.
3.14 Generation of trkA knockout mutant strains
The M. smegmatis trkA deletion was obtained by allelic replacement as described in
the literature [Menzies et al., 2009]. Briefly, 1.0-kbp fragments up- and down-stream
of the target gene were amplified by PCR with appropriate primers, 5’ fragment
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(DeltrkA5’F and DeltrkA5’R) and 3’ fragment (DeltrkA3’F and DeltrkA3’R). Both
fragments were cloned in-frame into the p2NIL vector. The resulting plasmid was
digested with PacI to insert a hyg sacB lacZ cassette from pGOAL19 and verified
by sequencing. The plasmid that harbored an in-frame deletion of the target gene,
termed p2NIL-∆trkA, was introduced into M. smegmatis wild-type strain mc2 155
and plated on Middlebrook 7H10 agar supplemented with kanamycin (25 µg/ml) and
hygromycin (50 µg/ml). Once single-crossover clones were obtained, they were grown
in Middlebrook 7H9 broth without antibiotics to allow a second crossover event.
Finally, cultures were diluted and counter-selected on 7H10 plates containing 10%
sucrose. Candidate colonies were tested for kanamycin and hygromycin sensitivity
and analyzed by PCR to confirm the unmarked deletion of trkA.
3.15 Generation of ich knockout mutant strains
Similar to the generation of trkA knockout mutant strains (∆trkA mutant), the frag-
ments up-and down-stream of the ich gene were amplified with primers, 5’ fragment
(Delkch5’F and Delkch5’R) and 3’ fragment (Delkch3’F and Delkch3’R). Then, they
were cloned into the p2NIL vector. The resulting plasmid was inserted a hyg sacB
lacZ cassette and verified by sequencing. Final plasmid p2NIL∆ich, then, was intro-
duced into M. smegmatis wild-type strain mc2 155 and colonies of a mutant with the
unmarked deletion of ich (4ich mutant) were selected as described above.
3.16 Generation of kch-trkA double knockout mu-
tant strains
In order to get the ich-trkA double knockout mutant strain, plasmid p2NIL-∆ich was
introduced into the M. smegmatis ∆trkA mutant. The double mutant ∆ich−∆trkA
was selected in the same way as to obtain the other single mutants ∆ich and ∆trkA.
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3.17 Complementation of mutant strains
A plasmid carrying the wild-type trkA gene was constructed to restore expression
of the gene in the 4trkA mutants. trkA was amplified by PCR from M. smegmatis
wild-type genomic DNA, using the forward primer trkAF and the reverse primer
trkAR. The PCR product was digested with NdeI and PstI and cloned directly into
the pVV16 vector [Telenti et al., 1993] to generate the complementation plasmid.
The resulting plasmid, pVV16-trkA, was introduced into the M. smegmatis 4trkA
mutant by electroporation. Transformants were selected on Middlebrook 7H10 agar
supplemented with kanamycin (25 µg/ml) and hygromycin (50 µg/ml).
The ich gene was amplified with oligos ichF and ichR. Then the PCR product was
digested with NdeI and PstI and coloned into the pVV16 vector. The pVV16-ich was
electroporated into the M. smegmatis 4ich mutant. Transformants were selected on
Middlebrook 7H10 agar supplemented with kanamycin (25 µg/ml) and hygromycin
(50 µg/ml).
3.18 Growth curves and competition experiments
M. smegmatis wild-type and mutants were cultured overnight and diluted (OD(600)
0.05) in 5 ml Middlebrook 7H9 medium, and growth curves performed in triplicate
for 24 hours at OD600.
Fitness of M. smegmatis strains was quantified in vitro by competition assays
in which overnight cultures of wild-type (rifampin-sensitive) and the 4trkA mutant
(rifampin-resistant) strains were diluted and adjusted to inoculate the same cell num-
bers in three mixed cultures of 5 ml 7H9 medium (initial OD(600) 0.05). Competition
cultures with the drug-resistant and drug-sensitive strains were incubated (37oC) and
10-fold serial dilutions plated after 0, 10 and 20 hours on Middlebrook 7H10 agar alone
or with rifampin (2 µg/ml). Colony-forming units (CFU) of the rifampin-resistant
4trkA strain were counted on drug-containing plates, while CFU counts of the wild
type were obtained after subtracting CFU for the 4trkA mutant from that for total
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viable cells on drug-free plates. The trkA mutant fitness was measured as the ratio
of the number of generations of the rifampin-resistant strain relative to that of the
wild type strain.
3.19 MIC determination
MIC for the M. smegmatis wild-type and mutant strains were determined in triplicate
in Middlebrook 7H10 agar supplemented with two-fold increasing concentrations of
antibiotics. Each strain was grown in Middlebrook 7H9 broth to logarithmic phase.
Cultures were diluted to yield a standard inoculum containing 106 CFU/ml, and
approximately 104 viable cells were plated on drug-containing and on drug-free plates.
The MIC of an antibiotic was defined as the lowest concentration at which no growth
was visible after 3-5 days under incubation. To analyze the effect of antibiotics on
cell survival, the number of CFU on drug-containing plates was divided by that for
viable cells on drug-free plates.
3.20 Membrane potential assay
For the membrane potential assay, three cultures of M. smegmatis wild-type and
mutant strains were grown to late logarithmic phase. Cultures were washed and
adjusted to the same number of cells ( 107 CFU/ml). Cell membrane potential was
estimated using the fluorescent probe rhodamine 123 (Sigma), [Morlock et al., 2000]
a lipophilic cationic molecule that is taken up into mycobacterial cells in response
to the level of the electrical potential [Cummings and Segal, 2004]. Inside the cells,
probe fluorescence is quenched.
To measure the degree of fluorescence decay, rhodamine 123 was added to samples
at a final concentration of 0.5 µg/ml. Time courses of fluorescence decay were ana-
lyzed by measuring the fluorescence decrease in the samples over a ten minutes long
period using a Tecan infinite F200 spectrofluorimeter (480 nm excitation and 530 nm
emission). The rate of fluorescence decay was normalized to the initial fluorescence
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and the fluorescence decay of the probe itself.
Moreover, the membrane potential was also measured via monitoring fluorescence
of rhodamine 123. This dye was added to the samples at a final concentration of 0.5
µg/ml. Then the fluorescence was measured in Tecan infinite F200 spectrofluorimeter
(480 nm excitation, 530 nm emission). Wild-type probe with additional valinomicin
was used as a control.
3.21 Estimating spontaneous mutant frequencies
For spontaneous mutant frequency estimation, approximately 103 cells from overnight
cultures were inoculated into three tubes with 5 ml Middlebrook 7H9 medium and
incubated (37oC). When cultures reached late logarithmic phase, cell aliquots were
plated on Middlebrook 7H10 agar supplemented with rifampin (50, 75 or 100 µg/ml)
and incubated (37oC, 3 to 5 days). Serial dilutions from cultures were also plated
on 7H10 agar without antibiotic to estimate the number of viable cells. Mutant
frequency was measured as the average number of rifampin-resistant colonies divided





4.1 Antibiotics induce mutagenesis in E. coli
4.1.1 Effect of different concentrations of antimicrobials on
E. coli mutagenesis
In principle, mutagenic activities of antimicrobials are expected to occur within a
window of concentrations very close to the MIC (peri-MIC), because higher concen-
trations will kill or stop the growth of most of the cells in the population and lower ones
will have not stimulatory effect [Couce and Blazquez, 2009]. In this work, we inves-
tigated the mutagenic effect of thirteen antimicrobials at peri-MIC concentrations on
the strain ME12, a MG1655 derivative, by evaluating the appearance of mutants resis-
tant to rifampicin and fosfomycin. We used the strain ME12 for consistence, because
it was used to study the effect of the same antibiotics on homologous recombination
[Lopez et al., 2007, Lopez and Blazquez, 2009]. This strain shows a spontaneous fre-
quency of rifampicin-resistant mutants of 2x10−7 and of fosfomycin-resistant mutants
of 1x10−6 (not shown). Table 4.1 shows the MIC of each antimicrobial under our ex-
perimental conditions for the strain ME12. The mutagenic effect was tested for five
different concentrations, including two below and two over the MIC and the MIC (i.e.
1/4xMIC, 1/2xMIC, MIC, 2xMIC and 4xMIC). The concentration of each antimicro-
bial producing the highest effect was re-tested using five independent replicates to con-
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Antibiotic ME12 ME124recA
Ampicillin (Amp) 1 1
Ceftazidime (Caz) 0.25 0.12
Imipenem (Imi) 0.12 0.12
Fosfomycin (Fos) 0.06 0.03
Ciprofloxacin (Cip) 0.12 0.007
Trimethoprim (Tri) 0.5 0.25
Sulfamethoxazol (Sul) 256 256
Tri/Sul (1/19)] 0.5/9.5 0.25/4.75
Colistin (Col) 8 2
Tetracycline (Tet) 0.5 0.5
Gentamicin (Gen) 0.5 0.5
Rifampicin (Rif) 2 2
Chloramphenicol (Chl) 2 2
Table 4.1: Minimal inhibitory concentrations (µg/ml) of the antimicrobials used
in this study against the wild-type strain ME12 and its recA-derivative.]: The
proportion trimethoprim/sulfamethoxazol is 1/19 as indicated by the EUCAST
http://eucast.www137.server1.mensemedia.net/clinical breakpoints
firm the results. Ten antimicrobials (ampicillin, ceftazidime, imipenem, fosfomycin,
ciprofloxacin, trimethoprim, sulfamethoxazole, trimethoprim/sulfamethoxazole, col-
istin and tetracycline) produced statistically significant increases (P ≤ 0.05) in the
mutant frequency when it was calculated for rifampicin-resistance, with maximal in-
creases of 3.4, 2.2, 3.0, 5.0, 2.0, 17.1, 6, 3, 8.7, 3.0 and 2.1-fold, respectively (Figure
4-1A, black bars).
The results from the other three drugs were not statistically significant (P >
0.05). When the mutagenic effect was studied calculating the mutant frequency
for fosfomycin-resistance, eight antimicrobials (ampicillin, ceftazidime, imipenem,
ciprofloxacin, trimethoprim, sulfamethoxazole, trimethoprim/sulfamethoxazole and
tetracycline) produced statistically significant increases (P ≤ 0.05) in the mutant
frequency, with maximal increases of 3.6, 2.0, 2.2, 2.2, 7.7, 4.9, 7.9 and 3.0-fold,
respectively (Figure 4-1B, black bars). The results from the other five drugs were
not statistically significant (P > 0.05). Taken together, these results indicate that
at least eight out of thirteen antimicrobials or combinations (those with positive re-
sults in both tests) produced increased mutagenesis levels at concentrations close to
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their MICs. Interestingly, while most antimicrobials produced mild increases in mu-
tagenesis, trimethoprim, sulfamethoxazole and the combination of trimethoprim plus
sulfamethoxazole produced the highest increases in mutant frequency in both tests
(rifampicin resistance and fosfomycin resistance). The resolution of filaments was
verified by direct observation of samples from the different cultures under the micro-
scope before plating, and only cultures with a proportion of filaments lower than 5%
of total cells were plated. Thus, increased mutant frequency is not attributable to
the presence of filamented cells in the treated cultures. A description of the effect of
antibiotic treatment on cell morphology can be found below.
As the number of viable bacteria in the inoculum (after antibiotic treatment)
might affect the observed frequency of mutants, we performed experiments with dif-
ferent inoculum sizes of untreated ME12 cells, ranging from 107 to 109 cells. No dif-
ferences were observed in the mutant frequencies among these cultures (not shown).
Thus, the final number of viable cells after treatment with different drugs was not
the cause of the observed antibiotic-mediated stimulation of mutagenesis.
Finally and remarkably, treatments with rifampicin or fosfomycin did not produce
an increased number of rifampicin-resistant or fosfomycin-resistant mutants, respec-
tively, thus indicating that the concentrations of these antibiotics and/or the time of
exposure used in our experiments were not able to select for rifampicin-resistant or
fosfomycin-resistant variants.
4.1.2 SOS induction by the different antimicrobials
In the literature, [Perez-Capilla et al., 2005, Ysern et al., 1990, Kohanski et al., 2007,
Miller et al., 2004, Gillespie et al., 2005], the induction of the SOS stress response by
some antimicrobials has been well investigated. However, in order to know whether
the observed stimulation of mutagenesis can be linked to an SOS induction, we stud-
ied the effects of these antimicrobials on the induction of recA transcription. We
used the disk-plate assay described in the Materials and Methods section. Figure 4-
2 shows that ampicillin, ceftazidimie, ciprofloxacin, trimethoprim, sulfamethoxazole
and trimethoprim plus sulfamethoxazole induce transcription of the recA::GFP fusion,
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Figure 4-1: Effect of sublethal concentrations of antimicrobials on mutant frequency.
Fold changes in mutant frequency of the wild-type (wt) strain ME12 (black bars)
and its recA mutant derivative (grey bars) for rifampicin resistance (RIFR) (a) and
fosfomycin resistance (FOSR) (b), after treatment with antibiotics. Data are relative
to untreated controls (no antibiotic). Only concentrations with the highest change in
mutant frequency are represented. The number in parentheses below the antibiotic in-
dicates the concentration relative to its MIC. Values are the means of five experiments
±SD. Asterisks indicate that the fold increases relative to the untreated strain are
statistically significant (P < 0.05), according to the MannWhitney U-test). AMP,
ampicillin; CAZ, ceftazidime; IPM, imipenem; CIP, ciprofloxacin; TMP, trimetho-
prim; SUL, sulfamethoxazole; SXT, trimethoprim/sulfamethoxazole; CST, colistin;
TET, tetracycline; GEN, gentamicin; CHL, chloramphenicol.
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Figure 4-2: Effects of antibiotics on the transcription of the recA::GFP fusion after
16 hours on solid surface. 100µl of an overnight culture were inoculated into LB-soft
agar (agar 0.7 %) and spread onto LB plates. Antibiotic-containing filter disks were
deposited onto the gelified agar, and plates were visualized through a blue-light lamp
after 16 hours of incubation at 37oC. Induction is observed as a fluorescent band
around the inhibition halo produced by Amp, Caz, Cip, Tri, Sul and Tri/Sul. This
assay permits the exploration of the full range of antibiotic concentrations for SOS
induction without knowing the most effective.The disks contain different amounts of
antibiotic (g): Amp (500), Caz (10), Imi (40), Fos (100), Cip (10), Tri (300), Sul
(3,200), Tri/Sul (13.5/256), Col (200), Tet (100), Gen (200), Rif (200) and Chl (300).
Disks containing no antibiotic and 10 g of mitomycin-C (Mito), a known inducer of
the SOS system, have been used as negative and positive controls, respectively.
with the highest induction produced by ciprofloxacin, trimethoprim and trimethoprim
plus sulfamethoxazole.
4.1.3 Effects of RecA on antibiotic-mediated stimulation of
mutagenesis
It has been demonstrated that ciprofloxacin and ceftazidime stimulate mutagenesis
in E. coli through the induction of mutagenic DNA-polymerases of the SOS system
[Perez-Capilla et al., 2005, Ysern et al., 1990]. Therefore, we studied the effects of
the different antimicrobials on mutant frequencies in a recA-deficient background.
As in the case of the wild-type strain, MICs of the different drugs were obtained
for the recA strain (Table 4.1). As we expected, a strong decrease in ciprofloxacin
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MIC was observed between the wild-type and its recA-deficient derivative. Also, a
slight decrease was observed in the MICs of ceftazidime, fosfomycin, trimethoprim,
trimethoprim/sulfamethoxazole and colistin.
The effects of drugs on the mutant frequency of the recA-deficient derivative were
studied with different peri-MIC concentrations, including the MIC itself. The mu-
tagenesis stimulated by ampicillin, imipenem, ciprofloxacin, trimethoprim, trimetho-
prim plus sulfamethoxazole and tetracycline is abolished in the recA background
(Figures 4-1). Gray bars show the results with concentrations equivalent to the
most mutagenic in the recA-proficient strain. None of the tested concentrations
showed an increased mutagenesis in the recA-deficient strain (except ceftazidime in
the rifampicin-resistance test). Therefore, RecA is absolutely necessary for the stim-
ulation of mutagenesis by the eight antimicrobials with the positive results in both
rifampicin-resistance and fosfomycin-resistance tests.
4.1.4 Effects of mutagenesis-stimulating concentrations of an-
timicrobials on cell morphology
We studied the effects of peri-MIC concentrations of antimicrobials on cell morphol-
ogy. The most stimulating concentrations are shown in Figure 4-3. Figure 4-3A shows
that ampicillin, ciprofloxacin, trimethoprim, sulfamethoxazole and trimethoprim plus
sulfamethoxazole, and the SOS-inducer Mitomycin-C (positive control) produced, as
expected, a clear filamentation of ME12 cells after 4 hours of treatments. A small
cell enlargement can be seen along with tetracycline. In addition, imipenem pro-
duced the classical ball-shaped cells. We also studied the effects of the corresponding
antimicrobial concentrations on the recA-deficient strain. Figure 4-3B shows that,
as predicted from its mechanism of action (inhibition of the septation process via
protein PBP3), ceftazidime also produced filaments in the recA mutant. Amazingly,
ciprofloxacin and trimethoprim (and sulfamethoxazole in a lesser extent) produced
filaments in the recA derivative, although shorter than in the wild-type. This is an
unexpected result as the production of filaments by these antibiotics was believed to
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Figure 4-3: Effects of antibiotics on cell morphology. Bacterial cultures were treated
for 4 hours as indicated in the Materials and Methods section. A: Effect on the wild-
type strain ME12. B: Effect on the ME12 recA derivative. Bars at the right bottom
of each image represent 10 µm.
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be caused by the induction of SOS system (see below). Thus, according to our results,
a recA-independent mechanism of filamentation can be predicted.
4.2 Antibiotic resistance in M. smegmatis
4.2.1 Screening for mutants
Generation transposon library
Transposon mutagenesis can be considered as a useful tool for bacterial genetic studies
because of the following reasons. First of all, an antibiotic marker of transposon is
an indicator that distinguishes mutants from wild-type. Secondly, transposon marks
its insertion sites, so the location of the changes can be easily isolated. Thirdly,
transposons can be constructed in order that recipient strains contain only a single
mutation. For example, the transposons can be constructed with the transposase
gene located outside of the transposon boundiries. When transposition occurs, the
transposase gene is lost together with the phage vector. Therefore, once the element
inserts in the chromosome it cannot transpose to a new site. Finally, these elements
can be designed to discover useful properties of bacteria such as the ability to form
transcriptional or translational fusions [Parish and Brown, 2011].
We have used ΦMycoMarT7 containing Himar1 -based mariner transposon to pro-
duce a large number of M. smegmatis mutants isolated after several independent
high efficient transduction events. So far, the analysis of the insertion sites from a
large number of mutants has revealed that transposon mutagenesis produced stable
mutants with no evidence of multiple insertions in each single strain. HimarI trans-
posons were inserted at random TA dinucleotides sites within the genome. There-
fore, there are a countable number of locations where the insertions can take place
[Sassetti et al., 2001].
Because the transposon has a kanamycin resistant cassette, the insertion mutant
can be selected on a medium supplemented with kanamycin 25 µg/ml; totally, we
generated an extensive transposon insertion mutant library of M. smegmatis mc2
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155 containing about 11.000 independent insertion mutants. The large number of
insertion mutants isolated by transposition covers more than two times the total
number of non-essential genes predicted in the M. smegmatis genome, with a high
probability (P > 0.9) that at least one insertion disrupts each target gene.
To verify the complexity of our insertion mutant library, we searched for and
selected mutant strains which may have an antibiotic resistant phenotype. The main
experimental results in this thesis were obtained when rifampicin is used to select the
rifampicin resistant mutants.
Identification of rifampicin resistant candidates
Rifampicin is one of the most powerful first line anti-TB drugs. The mutations
in the rpoB gene are the major mechanism of rifampicin resistance. However, as
we have discussed in the introduction section, there are alternative mechanisms of
rifampicin resistance which is not related to mutations in rpoB. Therefore, we probed
for rifampicin resistant mutants that can help us to discover the alternative mechanism
of resistance to rifampicin and understand in deep the role of these mutants in the
response to the other factors as an effect of other antibiotics.
For identification of the mycobacterial genes implicated in rifampicin resistance,
a transposon mutant library of M. smegmatis mc2 155 was screened to obtain mu-
tants with reduced rifampicin susceptibility. Each insertion mutant was replicated
on Middlebrook 7H10 agar plates supplemented with rifampicin (5, 10 or 20 µg/ml).
The growth of the M. smegmatis wild-type strain was completely inhibited at these
antibiotic concentrations (MIC of rifampicin for M. smegmatis mc2 155, 2 µg/ml);
nonetheless, dozens of insertion mutants with increased rifampicin resistance were
able to grow on plates containing 5 µg/ml rifampicin. Among them, 16 mutants grew
on plates supplemented with 10 µg/ml rifampicin. The rifampicin resistance pheno-
type of these strains was confirmed by MIC. Lastly, the three transposition mutants
with the highest degree of rifampicin resistance that grew well on 20 µg/ml rifampicin
were selected for further analysis.
To identify the disrupted gene in each strain, DNA sequences for each mutant were
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Locus Identity Number of strains MIC to rifampicin (µg/ml)
MSMEG 1945 Ionic channel Ich 1 20
MSMEG 2771 K+ regulator TrkA 2 20
Table 4.2: Rifampicin resistant candidates
compared with the M. smegmatis genome sequence as described in the materials and
methods section. Inside these genes, a high proportion of transposon insertion are
targeted to different gene locations as expected by random mutagenesis. However, a
few genes contain overlapping insertions in the same location, demonstrating a sub-
saturation level of gene inactivation. Rifampicin resistant candidates studied in this
thesis are listed in Table 4.2.
4.2.2 Analysis of interested rifampicin resistant candidates
trkA
From rifampicin resistant candidates, there were two selected mutants had indepen-
dent insertions disrupting the same target gene MSMEG 2771, which encodes a puta-
tive K+ transport regulatory protein (Figure 4-4a). One mutant harbored a transpo-
son insertion near the translation start codon (TA dinucleotide at position +7); the
other carried another transposon insertion in the middle of the gene (TA dinucleotide
at position +321). Both mutants showed the same level of rifampicin resistance (MIC
32 µg/ml), in accordance with a loss of gene function. Inactivation by transposition
of a gene that encodes a K+ transport protein thus confers increased resistance to
rifampicin in M. smegmatis.
Characterization of the trkA gene in rifampin resistance. The target gene
MSMEG2771, whose disruption increased M. smegmatis rifampin resistance, encodes
a TrkA protein with a K+ conductance regulatory domain (RCK). RCK proteins are
subunits that control K+ transporters in Bacteria, Archaea and Eukarya [Choe, 2002].
The core Trk system for K+ uptake in prokaryotes consists of two components: the in-
tegral membrane K+ translocating protein and the NAD+/NADH-binding peripheral
membrane protein TrkA [Dosch et al., 1991]. TrkA binds to the cytoplasmic portion
of the K+ membrane transporter, where it acts as an essential factor in K+ uptake
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Figure 4-4: Analysis of the M. smegmatis trkA gene. (A) Vertical arrows indicate
the location of transposon insertion in each rifampin-resistant mutant (number of
base pair in the trkA gene)(top). Domain organization of the TrkA protein, showing
the NAD(H)-binding motif sequence (bottom). (B) Alignment of TrkA sequences
from M. smegmatis (MSMEG 2771), M. tuberculosis (Rv2691) and E. coli. Asterisks
indicate identical residues.
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[Bossemeyer et al., 1989]. In E. coli, TrkA-mediated K+ transport is driven by proton
motive force and also requires a high ATP concentration [Rhoads and Epstein, 1977].
Analysis of the M. smegmatis TrkA sequence showed that the protein consists of
two tandemly arranged halves (RCK-N and RCK-C terminal; Figure 4-4A). The N-
terminal subdomain was predicted to form a Rossmann fold, similar to dehydrogenase
enzymes. This region has a nucleotide-binding sequence (Figure 4-4A), previously
identified as a flavin adenine dinucleotide-binding motif. This characteristic motif,
also present in the E. coli TrkA protein, binds NAD+ or NADH with high affinity
[Schlosser et al., 1993]. M. smegmatis TrkA protein shared considerable sequence
identity with other TrkA domain proteins, such as E. coli TrkA N-terminal (23%)
and M. tuberculosis CeoB (74%) (Figure 4-4B).
Deletion of the trkA gene decreases rifampin susceptibility in M. smeg-
matis. To establish that the loss of TrkA activity is responsible for enhancing ri-
fampin resistance in M. smegmatis, we generated an in-frame 4trkA deletion mutant.
Rifampin MIC for the wild-type strain and the 4trkA mutant were determined in
7H10 agar (Table 4.3). The trkA mutant showed considerable rifampin resistance
(32 µg/ml), with a 16-fold higher MIC of rifampin than the wild-type strain. Being
consistent with the absence of polar effects, the degree of resistance of the deletion
mutant was similar to that of the two insertion mutants. Analysis of survival curves
confirmed that 4trkA was highly viable when mutant cells were exposed to antibiotic
concentrations which killed the wild-type strain (Figure 4-5a).
The trkA gene from M. smegmatis wild-type strain mc2 155 was cloned into the
shuttle vector pVV16 and the resulting plasmid, pVV16-trkA, was introduced into the
4trkA strain. Plasmid expression of the trkA gene in the deletion mutant restored
rifampin susceptibility (MIC 2-4 µg/ml), but had no effect on the MIC of the wild
type strain, confirming that loss of trkA expression was the only factor responsible
for the rifampin resistance phenotype in M. smegmatis. These results demonstrate
that trkA gene inactivation increases M. smegmatis resistance to rifampin.
Deletion of the trkA gene confers isoniazid sensitivity in M. smegmatis.
Overexpression of the M. tuberculosis TrkA ortholog CeoB confers isoniazid resistance
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MIC (µg/ml) MIC (µg/ml)
Antibiotic Molecular weight LogS] mc2 155 4trkA
Novobiocin 612 -4.80 16 64
Rifampin 822 -4.09 2 32
Ofloxacin 361 -2.40 0.32 0.32
Ciprofloxacin 331 -2.39 0.32 0.32
Ethionamide 166 -2.30 32 32
Ethambutol 204 -1.43 2 2
Amikacin 585 -1.07 0.8 0.4
Streptomycin 581 -0.96 0.8 0.2
Kanamycin 484 -0.72 3.2 1.6
Capreomycin 1,321 n/a 6.4 1.6
Isoniazid 137 -0.59 128 32
Table 4.3: MIC of the main groups of antimycobacterial agents for M. smegmatis
wild-type mc2 155 and the 4trkA mutant. Antibiotics are ordered by solubility
values from hydrophobic to hydrophilic. ]: predicted solubility according to Drugbank
(http://www.drugbank.ca)
in an isoniazid-sensitive E. coli oxy R mutant [Chen and Bishai, 1998]. It has been
suggested that TrkA binds and sequesters isoniazid, preventing antibiotic attachment
to its target [Argyrou et al., 2006]. To examine the effect of trkA inactivation on iso-
niazid susceptibility, we determined the MIC of isoniazid for the wild-type strain and
the 4trkA mutant (Table 4.3). Although M. smegmatis shows intrinsic isoniazid tol-
erance, the 4trkA mutant was more sensitive to isoniazid (MIC 32 µg/ml), resulting
in a 4-fold decrease in MIC value compared to the wild-type strain (MIC 128 µg/ml).
This result was reflected by a sharp decrease in 4trkA viability when the mutant
cells were exposed to low antibiotic concentrations; in contrast, wild-type cells were
affected only moderately, even at high isoniazid concentrations (Figure 4-5b). This
result supports a function of TrkA as an element that protects mycobacterial cells
from the action of isoniazid.
M. smegmatis multidrug susceptibility is dependent on TrkA activity.
To explore the role of TrkA in the susceptibility pattern of M. smegmatis to distinct
antimycobacterial agents, we determined the MIC of a large number of antibiotics
for the 4trkA mutant; Table 4.3 shows the correlation of antibiotic activity with the
predicted hydrosolubility coefficients (LogS). Large hydrophobic antibiotics such as
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Figure 4-5: Survival (%) of M. smegmatis mc2 155 wild-type and the 4trkA mu-
tant under different concentrations of antibiotics. Percent of survivors of the wild-
type (black bars) and the 4trkA mutant (grey bars) to rifampin (A), isoniazid (B),
ciprofloxacin (C) and streptomycin (D) are shown. Survivors were determined by
plating serial dilutions on Middlebrock 7H10 agar plates with the indicated antibi-
otic concentrations, and represented as the percent of surviving cells (viable cells
determined on antibiotic-containing plates divided by total viable cells x100). The
asterisks indicate lack of growth on plates with the indicated antibiotic concentra-
tions, representing in all cases a survival of ≤ 0.0001%).
rifampin penetrate cells by passive diffusion; thus, reduced permeability to hydropho-
bic drugs could be responsible for the resistance phenotype in the trkA mutant. The
MIC of novobiocin, another highly hydrophobic drug, was increased 4-fold for the
4trkA mutant compared to that of the wild-type strain (Table 4.3). Less hydropho-
bic drugs with a large apolar core, such as fluoroquinolones (ciprofloxacin, ofloxacin),
were also less effective against the trkA mutant (Figure 4-5c), although there was no
change in the MIC.
In prokaryotes, cationic antimicrobial peptides, which bind to the negative charge
on the cytoplasmic membrane surface to disrupt the membrane, inhibit trkA mutants
more efficiently than wild-type strains [Parra-Lopez et al., 1994, Chen et al., 2004].
Aminoglycosides, another group of positively charged, very hydrophilic antimycobac-
terial drugs, killed the 4trkA mutant more efficiently than the M. smegmatis wild-
type strain. All aminoglycosides tested (kanamycin, amikacin, streptomycin and
capreomycin) showed lower MIC values for the 4trkA mutant than those of the wild-
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type strain, ranging from a 2-fold to 4-fold decrease (Table 4.3). M. smegmatis 4trkA
susceptibility to small hydrophilic drugs (ethambutol, ethionamide) or β-lactams was
unchanged.
These data indicate that trkA deletion affected the drug susceptibility pattern
of M. smegmatis, increasing resistance to hydrophobic antibiotics and sensitivity to
hydrophilic cationic agents. This suggests TrkA may influence the M. smegmatis
permeability barrier to antibiotics as a function of the chemical nature of the drug.
Growth, K+ requirement and fitness in the M. smegmatis trkA mutant.
Growth curves of M. smegmatis wild-type strain mc2 155 and the4trkA mutant show
a notable growth defect of the deletion strain (Figure 4-7a). The mutant had a lower
growth rate during the logarithmic phase than the wild-type strain, although both
showed the same cell density at stationary phase. The growth of the4trkA strain was
restored when additional K+ was supplied to the medium (Figure 4-7b). Addition
of KCl (10 to 100 mM) stimulated the growth of the 4trkA mutants but had no
effect on wild-type cells; at 200 mM KCl, the growth of the mutants and wild-type
strains was the same. These results suggest a reduced K+ uptake due to lack of
TrkA-mediated transport in the 4trkA mutant, and that it requires an additional
K+ supply to counterbalance its growth defect.
Resistance to antibiotics often has a fitness cost when the antibiotic is absent,
shown by the reduced growth of mutants relative to the wild-type strain in mixed
cultures [Andersson and Levin, 1999]. Competition experiments have shown that
all rifampin resistance mutations in the rpoB gene impose a cost in mycobacteria
[Billington et al., 1999, Gagneux et al., 2006], we thus examined whether trkA inac-
tivation had deleterious effects on bacterial fitness. As stated above, trkA inactivation
produces a notable growth defect. As expected, competition assays showed that the
wild-type was strongly outcompeted by the rifampin-resistant mutant during expo-
nential growth in mixed cultures. In these experiments, the relative fitness value of
the 4trkA mutant was 0.77 (Table 4.4).
TrkA is necessary for pH homeostasis in M. smegmatis. K+ uptake
maintains intracellular ionic balance in prokaryotes [Epstein, 2003]. K+ accumulation
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Figure 4-6: Growth curves and K+ effect on growth of mc2 155 and its 4trkA deriva-
tive. (A) Growth curves of M. smegmatis wild-type mc2 155 (closed circles) and
its 4trkA deletion mutant (open circles). (B) Effect of K+ addition (10-200 mM
KCl) on growth of mc2 155 (black bars) and 4trkA (grey bars). The ability of high
K+ concentrations to restore growth of the 4trkA mutant was measured in cultures
at mid-exponential phase (12 h). Values, optical density at 600 nm, (OD600) are
mean±SD of three experiments.
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Competition cultures
Strain No. of divisions Doubling time (hours) Relative fitness
mc2 155 6.87 2.91 1.00±0.02
4trkA 5.32 3.76 0.77±0.02
Table 4.4: Fitness of M. smegmatis mc2 155 and its 4trkA-derivative during the
logarithmic growth phase. Strains were grown in mixed cultures until late logarithmic
phase (three independent experiments). The number of divisions and the doubling
time of each strain were obtained from CFU counts on drug-containing and drug-
free plates. The 4trkA mutant fitness was measured as the ratio of the number of
generations of the rifampin-resistant strain relative to those of the wild type strain.
is essential for intracellular pH homeostasis, and loss of K+ uptake can thus increase
sensitivity to acidic conditions. We studied trkA knockout mutant growth over a
range of pH values (pH 5-8; Figure 4-7A). At neutral pH, the 4trkA mutant’s growth
was reduced compared to that of the wild-type strain. At acid pH, the mutant’s
growth was severely impaired, while the wild-type strain growth was reduced only
slightly. Wild-type cells were able to grow even at pH 5, at which the 4trkA mutant
growth was completely inhibited. In contrast, at alkaline with pH equal to 8, 4trkA
mutant growth was nearly identical to that of wild-type strain, with no visible growth
defect. The reduced growth of the 4trkA mutant at acid pH was compensated when
supplementary K+ was added to the medium. For instance, Figure 4-7B shows how
different concentrations of K+ counterbalance the growth defect of the 4trkA mutant
at pH 5.5. These results suggest that TrkA-dependent K+ uptake counteracts the
decrease in intracellular pH when cells are exposed to low pH values; as K+ tends to
increase intracellular pH, the K+ uptake requirement decreases at higher pH.
TrkA inactivation leads to hyperpolarization of the cytoplasmic mem-
brane. PMF is an electrochemical ion gradient across the membrane, with an electri-
cal component (4ψ inside negative) and a chemical gradient (4pH, inside alkaline).
The membrane is separated from the bulk aqueous phase by a barrier of electro-
static nature that could serve as a storage for protons [Mulkidjanian et al., 2006].
TrkA-dependent K+ uptake is needed to maintain constant PMF values in prokary-
otes [Bakker and Mangerich, 1981]. The K+ uptake rate has a direct influence on
the electrical membrane potential, the main contributor to PMF when cells grow in
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Figure 4-7: Growth curves and K+ effect on growth of mc2 155 and its 4trkA deriva-
tive. (A) Growth curves of M. smegmatis wild-type mc2 155 (closed circles) and
its 4trkA deletion mutant (open circles). (B) Effect of K+ addition (10-200 mM
KCl) on growth of mc2 155 (black bars) and 4trkA (grey bars). The ability of high
K+ concentrations to restore growth of the 4trkA mutant was measured in cultures
at mid-exponential phase (12 h). Values, optical density at 600 nm, (OD600) are
mean±SD of three experiments.
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Figure 4-8: Membrane potential assay. (a) Exponentially growing cultures of M.
smegmatis wild-type mc2 155 (closed circles) and its 4trkA derivative (open circles)
were incubated with rhodamine 123. The curves, monitored for 10 min, show the
decrease in fluorescence emission produced by intracellular quenching of the probe. .
(b) Effect of K+ addition (50-200 mM KCl) on membrane potential of mc2 155 and
4trkA. Cells were pre-incubated for 30 minutes with increasing KCl concentrations
(50-200 mM KCl). Fluorescence decay was measured after 10 minutes of incubation
with rhodamine 123. Values show the mean ±SD.
a neutral environment. To explore the effect of trkA inactivation on cell membrane
electric properties in M. smegmatis, we estimated the electrochemical potential gen-
erated across the membrane by monitoring fluorescence quenching of rhodamine 123.
Cells with higher membrane potential (increased interior negative charge) accumulate
the cationic probe rhodamine 123 more efficiently, leading to the decreased intensity
of fluorescence emission (28); the rate of fluorescence decay is thus proportional to
the electrical membrane potential.
Compared with wild-type cells, the 4trkA cells showed increased rhodamine 123
uptake and, thus, enhanced fluorescence decay (Figure 4-8); these data indicate that
the trkA mutant has a hyperpolarized cell membrane. Thus, loss of TrkA-dependent
K+ uptake is responsible for the increased electrical membrane potential in the M.
smegmatis 4trkA strain. The high negative charge of the intracellular membrane
in the trkA mutant is consistent with its previously known multidrug susceptibility
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pattern (susceptibility to cationic agents and resistance to hydrophobic drugs).
Additionally, the cells were pre-incubated for 30 minutes with increasing K+ con-
centrations (50, 100 and 200 mM KCl). The addition of K+ to the medium depolarizes
the bacterial membrane, leading to a strong decrease in the diffusion of the probe in-
side the cells and, consequently, to a reduced fluorescence decay in the samples (Figure
4-8). As expected, the trkA mutant maintains higher levels of membrane potential
when compared with wild-type cells at each KCl concentration.
We have studied the effects of an H+ ionophore, carbonyl cyanide m-chlorophenyl
hydrazone (CCCP), against M. smegmatis wild-type and the trkA mutant. CCCP
destroys membrane potential by eliminating the proton H+ gradient. Although the
M. smegmatis trkA mutant had a hyperpolarized membrane, the susceptibility of
both strains to CCCP was similar (MIC 4 µg/ml). Finally, we analysed the effect of
K+ ionophore and nigericin. This compound has a very high affinity for monovalent
cations, such as K+, and catalyses the electroneutral exchange of intracellular K+ for
H+ (antiporter). Therefore, nigericin reduces intracellular K+ levels, disrupts mem-
brane potential and decreases intracellular pH. As expected, the trkA mutant showed
a hypersusceptibility to the K+ ionophore nigericin (MIC 4 µg/ml), compared with
the wild-type cells (MIC 16 µg/ml). The trkA mutant was unable to counterbal-
ance the K+ eﬄux due to its impaired K+ uptake, leading to severe defects in the
membrane potential and intracellular pH.
Ich
The other rifampicin candidate from our library was a mutant with an insertion in
the ich gene which encodes a putative K+ transport protein (Figure 4-9). The gene
was inactivated by the insertion of TA dinucleotide at position +1066. Because of
the loss of function of the gene, the mutant showed a rifampicin resistant phenotype
with MIC around 32µg/ml.
Sequence analysis of Ich protein encoded by MSMEG 1945 reveals
identity with potassium transporter protein. The gene MSMEG 1945 en-
codes an ionic channel protein with TrkA-N domain (K+ conductance regulator
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Ion transport TrkA RCK-N 
M. smemagtis MSMEG_1945 1095bp 
M. smemagtis Ich 364 aa 
MycoMarT7(+1066) 
Figure 4-9: Location of transposon insertion. Vertical arrows indicate the location
of transposon insertion in a rifampin-resistant mutant (number of base pair in the
ich gene)(top). Domain organization of the Ich protein, showing the TrkA-N domain
(bottom).
domain RCK-N which controls K+ transporters in Bacteria, Archaea and Eukarya
[Choe, 2002]. The analysis of the sequence of the M. smegmatis protein Ich encoded
by MSMEG 1945 showed that the protein contains two domains: one is ion trans-
porter locating in the membrane; the other is TrkA-N domain locating on cytoplasm.
Moreover, search for the homologues of this protein by protein blast (BLASTp) re-
vealed identity with proteins implicated in the potassium transport. We found that
the Ich protein has considerable sequence identity with the protein tranmembrane
cation transporter in M. tuberculosis (70%) with Kch of M. massiliense (74%) and
Kch of E. coli (22%). In E. coli Kch protein is a potassium transporter similar to a
group of eukaryotic K+ channel proteins [Milkman, 1994]. It takes part in the reg-
ulation of membrane potential under certain stress and its overproduction leads to
the increase of potassium permeability of cells [Kuo et al., 2005, Ungar et al., 2001,
Kuo et al., 2005].
Deletion of ich increases resistance of M.smegmatis to rifampicin. Our
analysis of insertion mutants of ich from our insertion library showed that the mutants
with interruption in ich increased their resistance to rifampicin with MICs over 20
71
mg /ml. To avoid polar effects of the result, an in-frame knock out ich mutant was
constructed. The MICs to rifampicin of the wild type strain and the ich deletion
strain were determined in Middlebrook with MIC roughly 32 µg/ml. Meanwhile,
rifampicin MIC of wild type strain was only 2 µg/ml that was 16 folds lower than
rifampicin MIC of ich mutants.
Plasmid pvv16 with the cloned ich gene was transformed into Ich knock out mu-
tant. The expression of pvv16 -ich in the mutant strain recovered the phenotype of
wild type. This result demonstrates that deletion of ich gene may be one of the key
factors of resistance to rifampicin in M. smegmatis.
Mutant with ich deletion increase the susceptibility to isoniazide and
ethionamde. Recent results by [Argyrou et al., 2006] suggested that TrkA binds
and isolates isoniazid. Our previous work further showed that mutants lacking of
the trkA gene became isoniazid susceptibility in M. smegmatis with MIC 64 µg/ml
[Castaneda-G’arcia et al., 2011]. As ich contains TrkA domain, it may also have
tight relations with isoniazid susceptibility like trkA does. Therefore, in this work, we
performed several analyses to reveal the effect of ich together with trkA on isoniazid.
First, besides ich deletion mutant, we created a double mutant with deletion of
both genes ich and trkA. Subsequently, MICs to isoniazid of ich deletion mutant
and double mutant ich-trkA were acquired. While wild type strain of M. smegmatis
showed resistances to isoniazid with MIC 128 µg/ml, both ich deletion and ich-trkA
mutants were considerably more susceptible to isoniazid with MICs 8 µg/ml and 2
µg/ml respectively. Comparing to the acquired MIC at 64 µg/ml on the mutants
lacking of the trkA gene alone, these numbers are significantly smaller.
Ethionamide is structurally similar to INH and also is an inhibitor of mycolic acid
biosynthesis. The MICs to ethionamide of ∆ich and ∆ich-∆trkA were determined.
We found that both of mutants were more susceptible to ethionamide than wild-type.
Indeed the obtained MICs were 16 µg/ml and 8 µg/ml for ∆ich and ∆ich-∆trkA,
respectively; when the MIC of wild-type was 64 µg/ml. This result suggested that




Antibiotics mc2 155 4ich 4ich-4trkA 4ich-pvv16 ich
Novobiocin 32 64 64 32
Rifampicin 4 32 32 8
Ofloxacin 0.32 0.32 0.32 0.32
ciprofloxacin 0.32 0.32 0.32 0.32
Ethionamid 32 8 4 32
ethambutol 2 2 2 2
Amikacin 0.8 0.4 0.4 0.8
streptomycin 0.8 0,2 0,2 0.4
Kanamycin 3.2 1.6 1.6 —
Isoniazid 128 8 2 128
Table 4.5: MIC of the main group of antimycobacterial agents for M. smegmatis
wild-type mc2 155, the 4ich, the 4ich-4trkA mutants and the complementation
strain of the 4ich. Antibiotics are ordered by solubility values from hydrophobic to
hydrophilic.
The role of the ich gene in antibiotic resistance profile of M. smegmatis.
In order to investigate the functions of ich and ich together with the trkA genes, MICs
of mutants ∆ich and ∆ich-∆trkA with respect to various antibiotics were determined.
Table 4.5 shows the obtained results in our experiments. Hydrophobic antibiotics
such as novobiocin and rifampicin are able to pass through the outer membrane to
the cell by passive diffusion. Meanwhile, the penetration of hydrophilic antibiotics is
significant low. Our first observation showed that the mutants were more resistant to
hydrophobic antibiotics than hydrophilic antibiotics.
In particular, inactivation of ich and double mutants were resistant to hydrophobic
antibiotics such as novobiocin and rifampicin with two-fold and eight-fold increase in
MIC. Less hydrophobic antibiotics, such as fluoroquilones almost do not have any
effect on mutants with no change in MICs. On the other hand, aminoglycosides with
high hydrophilic properties killed the mutants more effectively than wild type strain
with two-fold decrease in MIC. However, with the other small hydrophilic antibiotics,
such as ethambutol and β-lactams we obtained the same MICs as wild type.
In addition, we also analyzed the viability of wild type, ∆ich and ∆ich-∆trkA
mutants on different concentrations of several antibiotics ranging from hydrophobic to
































































wt ∆ich ∆ich-∆trkA 
Figure 4-10: Viability (%) of M. smegmatis mc2 155 wild-type, 4ich and 4ich-
4trkA mutants under different concentrations of antibiotics. Percentage of viabilities
of the wild-type (blue bars), 4ich (red bars) and the 4ich-4trkA mutant (yellow
bars) to rifampin (A), isoniazid (B), ciprofloxacin (C) ) at the indicated antibiotic
concentrations are shown.
on different concentrations of rifampicin is much larger than viable count of wild
type. This result again explains the MIC numbers of these strains shown in Table. It
demonstrates that ich plays an important role in protection of M. smegmatis against
rifampicin.
As we observe in Figure 4-10, although there is no change in MICs of all the strains
to fluoroquilones, viable count of mutants to high concentrations of ciprofloxacin
closed to the MIC is significantly larger than wild type. The results in this figure
show that those antibiotics are less effective on ∆ich and ∆ich-∆trkA mutants.
The difference between isoniazid MIC of ∆ich and ∆ich-∆trkA mutants and wild
type is supported by the viability count of those strains. In fact, in Figure 4-10 the
viability of these mutants reduces dramatically when the concentration of antibiotics
is increased. Meanwhile, the effect of isoniazid acting on the viability of wild type is
negligible even at high concentration.
Complementation strain with expression of plasmid pvv16-IC restores all the wild
type phenotypes. In summary, the reaction of ∆ich mutant and double mutant
∆ich-∆trkA under the impact of different antibiotics demonstrates that ich gene
together with the trkA gene play an important role in uptake of both hydrophobic
and hydrophilic antibiotics.
Growth effect and K+ requirement. To study the growth effect of ∆ich
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Table 4.6: The growth rates and doubling time of the mc2 155, the 4ich and the
4ich-4trkA mutants. The growth rate was estimated as the maximum slope of the
natural logarithm of optical densities versus time
and ∆ich-∆trkA mutants, growth curves were plotted for 24 hours. The obtained
growth curves of mutants and wild type are different. In particular, the ∆ich and
∆ich-∆trkA mutants have notable lower growth rate than wild type.
According to [Andersson and Levin, 1999, Levin et al., 2000], antibiotic resistance
is usually related to physiological cost for the bacteria. When bacteria are exposed
to antibiotics, mutations conferring antibiotic resistance give the bacteria advan-
tages over susceptible ones. Quantification of fitness cost is one of the methods
to investigate the evolution of antibiotic resistance and its stability in a population
[Pope et al., 2010]. To evaluate the fitness cost associated with antibiotic resistance
the growth rate and doubling time of bacteria were calculated. From the growth
curves, the growth rate was estimated as the maximum slope of the natural loga-
rithm of optical densities at 600 nm versus time. The obtained results are showed
in Table 4.6. According to that table, the growth rate of mutants is lower than the
growth rate of wild-type and the mutants need more time to reach a double optical
density value than the wild-type.
When K+ was added into the medium at different concentrations the growth rate
of mutants increased. However, although adding K+ helps mutants to grow faster, it
almost does not have any effect on the growth rate of wild type. This result shows
that bacteria lacking of the ich gene require more K+ to grow.
Loss of the Ich gene causes increase sensitivity to acidic pH. Potas-
sium and acid-base balance were known to be interrelated. At low internal pH, cells
exchange intracellular protons for extracellular K+ [Kashket and Barker, 1977], an
optimal accumulation of K+ is essential in bacteria for the maintenance of internal
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Figure 4-11: Growth curves and K+ effect on the growth of the mc2 155, the 4ich
and the 4ich-4trkA mutants. (A) Growth curves of M. smegmatis wild-type mc2
155 (blue colors), 4ich (red colors) and 4ich-4trkA(yellow colors). (B) The effect
of K+ addition (10-200 mM KCl) on the growth of mc2 155 (blue bars), 4ich (red
bars) and4ich-4trkA (yellow bars). The ability of high K+ concentrations to restore
growth of the mutants was measured in cultures at mid-exponential phase (12 hours).
Values, optical density at 600 nm, (OD 600) mean ±SD.
increase the sensitivity of bacteria when they are exposed to acidic conditions. To
examine the functions of ich in regulation of internal pH, the 4ich and 4ich-4trkA
mutants were grown in liquid media with pH ranging from 5 to 8. The growth of
different strains are plotted in Figure 4-11. At neutral pH, the mutants grew slower
than wild type. When bacteria are grown in acid pH, the growth of mutants reduces
significantly while the growth of the wild type only changes slightly. On the other
hand, at alkaline pH the growth of the mutants almost reached the growth of the wild
type.
In addition, the growth of mutants in the medium at pH 5.5 with different concen-
tration of K+ was also compared to that of wild-type (Figure 4-12). In the presence
of K+ the mutants grew better. However, even when 25mM of K+ was added to
the medium the mutants could not get the growth level of the wild-type. Only at
100mM of K+ the growth of 4ich mutant almost reached the the growth level of
the wild-type. The aforementioned result indicates that the ich gene is important for
potassium-dependent growth of M. smegmatis at low pH values.
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(A) (B) 
Figure 4-12: Effect of extracellular pH on growth of the 4ich and the 4ich-4trkA
mutants. (A) Effect of pH (5.0 to 8.0) on the growth of mc2 155 (blue bars), 4ich
(red bars) and 4ich-4trkA (yellow bars) in Middlebrook 7H9 liquid medium (initial
OD600 0.05). (B) Effect of K+ addition (10-100 mM KCl) on the growth of mc2
155 (blue bars), 4ich (red bars) and 4ich-4trkA (yellow bars) at pH 5.5. Optical
density (OD600) was measured after 12 hours incubation at 37oC. Values show the
mean±SD
tributed by two factors: an electrical component (4ψ, inside negative) and a chem-
ical gradient (4pH, inside alkaline). The uptake of K+ directly relates to elec-
trical membrane potential, maintaining the optimal transport of K+ is one of the
obligators for electrical membrane potential value, the main contributor to PMF
when cells grow in a neutral environment [Bakker and Mangerich, 1981]. We have
already studied the function of trkA in regulation of electrical membrane potential
[Castaneda-G’arcia et al., 2011]. Following that result, we will also examine the effect
of ich deletion on membrane potential properties in this work.
Particularly, we measured electrochemical membrane potentials across membrane
by monitoring fluorescence of rhodamine 123. Cells with higher membrane potential,
i.e. with charging more negatively inside, accumulated a higher number of the cationic
rhodamine 123. The florescence of rhodamine 123 in the medium was monitored. The
medium containing cells with high membrane potential had low fluorescence. Besides,
the K+ ionophore (valinomycin) was used for the positive control probe.
When valinomycin was added to the medium (without K+ or with concentration
of K+ less than in the cells), it forced the cells to take K+ out. In that way, the
negative charge inside the cells increased leading to an increase of membrane potential.
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Figure 4-13: Membrane potential assay. Exponentially growing cultures (without
KCl) of M. smegmatis mc2 155 (blue bars), 4ich(red bars) and 4ich-4trkA (yellow
bars) were incubated with rhodamine 123. The curves show the decrease in fluores-
cence emission produced by intracellular quenching of the probe. Effect of K+ addi-
tion (100 mM KCl) on the membrane potential of mc2 155, 4ich and 4ich-4trkA.
Cells were pre-incubated for 30 min with increasing KCl concentrations. Fluorescence
measured with rhodamine 123. Values show the mean±SD of experiments
rhodamine 123. Accordingly, rhodamine 123 in the medium decreased. At the end,
compared to wild type, the medium of the positive control probe presented with lower
fluorescence.
Similar to the positive control probe, mutant strains ∆ich and ∆ich-∆trkA also
showed a decrease of fluorescence. Indeed, they accumulated more rhodamine 123
and possessed higher membrane potential. The higher negative inside of the ∆ich
and ∆ich-∆trkA mutants can be considered as a reasonable explanation for the ob-





5.1 Antibiotics and mutagenesis
Over the past six decades, the extensive usage of antimicrobial drugs has estab-
lished a major impact on human-associated bacteria including both commensal and
pathogens, leading to the selection and the wide spread of resistant variants. The
frequent exposure of bacteria to different antibacterial agents results in the selec-
tion of preexisting resistant variants that ultimately become fixed in the population
[Lederberg and Lederberg, 1952, Newcombe, 1949]. Under antibiotic stresses, many
bacteria with an increased mutation rate (hypermutators) survive and become resis-
tant to the antibiotics [Mao et al., 1997].
The induction of the SOS response by antimicrobials, such as fluoroquinolones,
and its consequence, i.e. the increased mutagenesis, were described in the litera-
ture long time ago [Ysern et al., 1990]. Since the SOS response is efficiently acti-
vated by DNA-damaging agents leading to the transcriptional induction of the error-
prone DNA-polymerases, it is not surprising that clear evidence of antimicrobial-
induced mutagenesis was first described with fluoroquinolones [Ysern et al., 1990,
Power and Phillips, 1993]. However, the induction of the SOS response, and its di-
rect consequence, i.e. the increased mutagenesis caused by β-lactams have just been
recently revealed in the literature [Perez-Capilla et al., 2005, Miller et al., 2004].
Recent work by [Kohanski et al., 2007] has demonstrated that some antimicro-
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bials, defined as bactericidal, such as ampicillin, norfloxacin and kanamycin, stimu-
late the production of highly deleterious ROS radicals in Gram-negative and Gram-
positive bacteria, which ultimately can contribute to cell deaths. On the contrary, bac-
teriostatic drugs do not produce such effects. Besides, it also shows that the same bac-
tericidal drugs induce the SOS stress response and that the inactivation of RecA, a co-
regulator of the response, produces an increased susceptibility to some of them, includ-
ing norfloxacin, ampicillin and kanamycin [Kohanski et al., 2007, Lewin et al., 1989].
In this work, our results discovered an additional interesting fact that mutagenesis
is not only induced by bactericidal drugs but also by bacteriostatic ones, and that
inactivation of RecA activity abolishes the induction of mutagenesis in all cases.
Another interesting result from our investigation is that trimethoprim, either alone
or in combination with sulfamethoxazole, promotes the highest increase in mutant
frequency (Figures 4-1A and 4-1B). Trimethoprim prevents incorporation of thymine
into bacterial DNA by inhibition of dihydrofolate reductase [Amyes and Smith, 1974].
It not only provokes the induction of the SOS response [Lewin and Amyes, 1991]
but also the nucleotide pool imbalance which may affect the replication fidelity
[Lewin and Amyes, 1991]. Therefore, both SOS response and nucleotide imbalance
might act synergistically to the increase of mutant frequency. The other interest-
ing result is the production of filaments in the recA derivative by ciprofloxacin and
trimethoprim treatments. In particular, the production of filaments by these an-
tibiotics was believed to be caused by the SOS response, which was mediated by
RecA and LexA. This response induces the transcription of the sulA (sfiA) gene
[Peterson et al., 1985, Kunz and Kohalmi, 1991]. SulA interacts reversibly with the
protein FtsZ causing the inhibition of cell division and the consequent filamentation
[Huisman and D’Ari, 1981]. A sulA-independent filamentation is also discovered in E.
coli, the mechanism of which is also dependent on SOS induction [Kawarai et al., 2004].
Our results suggest that a new SOS-independent mechanism mediates filamentation
in the absence of RecA. In fact, we have discovered that, at least for ciprofloxacin,
filamentation occurs in a sulA-deficient background (not shown).
Moreover, we show that a number of antibiotics can increase genetic variation by
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the stimulation of mutagenesis in the treated bacteria, suggesting that antibiotic treat-
ments may favor the acquisition and/or the evolution of antibiotic resistance in bacte-
ria. For instance, some extended-spectrum β-lactamases are the result of combining
a reduced number of mutations [Morosini et al., 1996, Morosini et al., 1998]. Thus,
sub-lethal concentrations of mutagenic antimicrobials (not necessarily β-lactams) may
accelerate the evolution of new extended-spectrum variants by stimulating the produc-
tion and the accumulation of mutations. Another example is the resistance conferred
by the increased expression of eﬄux pumps. It can occur via mutation in different
targets, including mutations in the local repressor gene, mutation in a non-related
global regulatory gene and changes in the promoter region of the eﬄux-pump gene
(see for instance reference [Piddock, 2006]).
The stimulatory effect on mutagenesis described in this work for some of the tested
antimicrobials is very low, and may be considered too modest to exert any effect on
bacterial evolution. However, it has been stated that modest changes in mutation
rate can influence antibiotic resistance developments greatly [Denamur et al., 2005].
Concerning the possibility of finding the stimulatory concentrations by a sufficiently
dense bacterial population, we have studied a vast amount of bacteria challenged by
antibiotic treatments. Antibiotics are mainly used to combat pathogens but they
also challenge commensals collaterally. While an infection is usually produced by
a relatively small number of cells (108-109), about 1014 prokaryotic cells from hun-
dreds of different species conform our commensal flora with different intrinsic levels
of antibiotic susceptibility [Andremont, 2003]. Finally, even resistant microorganisms
might be included among the possible targets for the mutagenic effect of antibiotics
as high concentrations of antibiotics must be considered sub-lethal for resistant bac-
teria. Thus, any particular window of sub-MIC mutation-stimulating concentrations
of antibiotics should not be difficult to find. The fact that thousand of tons of antibi-
otics are used every year to treat billions of human and veterinary infections and to
promote animal growth, increases the probability of finding the suitable conditions
for the stimulation of mutagenesis.
Studies by Romesberg and coworkers have shown that prevention of SOS acti-
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vation resulted in decrease of both survival and mutagenesis in ciprofloxacin-treated
cultures, as well as ciprofloxacin or rifampicin-treated infected mice [Cirz et al., 2005,
Cirz and Romesberg, 2006]. Consequently, the possibility that components of in-
duced mutation pathways might be inhibited as a novel therapeutic strategy to pre-
vent the development of antibiotic resistance has been proposed in the literature
[Cirz and Romesberg, 2007]. Efforts have been made to identify small molecules
and short peptide inhibitors of RecA activity, although the absence of potential
adverse effects on Rad51 (the human RecA homologue) needs to be demonstrated
[Wigle and Singleton, 2007, Wigle et al., 2009].
Our study aimed at exploring the effect of RecA inhibition on the induced mutage-
nesis produced by many antibiotics. Our results with the recA-defective strain suggest
that most, if not all, mutagenesis induced by sublethal concentrations of antibiotics
is dependent, directly or indirectly, on RecA activity, thus supporting the hypothesis
that inhibition of RecA is a plausible therapeutic adjuvant in combined therapy to
reduce the capacity for generating antibiotic resistant mutants, with additional advan-
tages of affecting sensitivity, homologous recombination [Kowalczykowski et al., 1994],
swarming motility, [Gomez-Gomez et al., 2007] and biofilms [Boles et al., 2004].
5.2 Antibiotic resistance of M. smegmatis
In this study, we tried to identify the mechanisms which could provide acquired
antibiotic resistance of mycobacteria. We analyzed a M. smegmatis mutant library for
rifampicin resistance. We found 16 transposon mutants that increased the resistance
of M. smegmatis to rifampicin from our insertion mutant library. Among them, we
studied two independent insertion mutants carried insertions within the same target
gene, trkA (MSMEG 2771), predicted to encode a regulator of K+ uptake and one
mutant having insertion in the ich gene predicted to encode a K+ transporter. The
level of antibiotic resistance was identical (16-fold increase) in the 4trkA in-frame
deletion mutant, which was complemented by the wild-type trkA gene. The 4ich in-
frame deletion mutant also has a high level of rifampicin resistance (16 fold increase).
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This mutant then was complemented by the ich gene of the wild-type strain.
5.2.1 TrkA
Our results show that TrkA is necessary for K+ uptake in M. smegmatis, in accordance
with studies that indicate it is essential for K+ accumulation in prokaryotes, which
need a high intracellular K+ concentration (0.1-1 M) for survival [Dosch et al., 1991,
Parra-Lopez et al., 1994, Chen et al., 2004, Nakamura et al., 1998]. Here, we show
that the M. smegmatis trkA mutant requires an additional K+ supply to counterbal-
ance its growth defect and its susceptibility to acidic pH. Given the K+ deficiency
in 4trkA cells, we suggest that TrkA-dependent ion acquisition is central to the
maintenance of adequate K+ levels in M. smegmatis.
In bacteria, proteins involved in basic physiological functions have an essen-
tial role in intrinsic resistance to antibiotics and the acquisition of antibiotic re-
sistance [Fajardo et al., 2008, Liu et al., 2010]. Here, we demonstrate that in ad-
dition to increased rifampicin resistance, the M. smegmatis 4trkA mutant exhibits
enhanced isoniazid susceptibility. Interestingly, overexpression of CeoB, the M. tu-
berculosis TrkA homologue, confers isoniazid resistance in an E. coli oxy R mutant
[Chen and Bishai, 1998]. This effect was suggested to be due to TrkA sequestration
of isoniazid, as it is chemically similar to the NAD+ nucleotide. 35 This hypothesis is
supported by a recent study in which TrkA showed high affinity for active isoniazid
adducts in complex with NAD(P)+ [Argyrou et al., 2006]. Another group suggests
that flavin adenine dinucleotide-binding proteins also influence NADH/NAD+ lev-
els, and, hence, modify isoniazid activation and binding to its main target, InhA,
through nucleotide competition [Miesel et al., 1998, Vilcheze et al., 2005]. Our re-
sults indicate that the mycobacterial protein TrkA protects cells from the first-line
antibiotic isoniazid, increasing tolerance of this drug by M. smegmatis. In addition to
the previously proposed mechanisms, our results suggest that the chemical properties
of isoniazid (high solubility and polarity) influence its penetration inside M. smegma-
tis and, thus, it could contribute to explain why the trkA mutant is more susceptible
(see below).
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TrkA is necessary for intrinsic resistance to a number of positively charged antibi-
otics in prokaryotes, such as polycationic antimicrobial peptides in E. coli, Salmonella
enterica and Vibrio vulnificus [Parra-Lopez et al., 1994, Chen et al., 2004] or amino-
glycosides in Pseudomonas aeruginosa [Lee et al., 2009]. We found that loss of TrkA
activity modifies M. smegmatis susceptibility to a wide variety of antibiotics. The
M. smegmatis 4trkA mutant showed hypersusceptibility to cationic agents, such
as aminoglycosides, and increased resistance to large hydrophobic antibiotics, in-
cluding rifampicin, novobiocin and fluoroquinolones. In E. coli, Trk proteins, in-
cluding TrkA, are also associated with a general function in antibiotic susceptibility
[Girgis et al., 2009]. Disruption of the Trk system increased antibiotic tolerance when
E. coli cells were exposed to sublethal concentrations of several classes of antibiotics
with different targets (nalidixic acid, piperacillin, tetracycline and doxytetracycline),
although the molecular basis of this effect was not identified [Girgis et al., 2009]. K+
uptake via the TrkA system has a major role in bacterial physiology [Epstein, 2003,
Su et al., 2009] as it has a function in osmotic stress tolerance, internal pH mainte-
nance, the regulation of protein activity and the control of bacterial virulence. M.
smegmatis maintains intracellular pH near neutral and a constant PMF through in-
terconversion of the membrane electrical potential to a pH gradient.
Here, we show that TrkA activity counteracts the effect of extracellular acidic pH
in M. smegmatis and, hence, participates in controlling intracellular ionic balance.
Our results strongly suggest that in the absence of TrkA-dependent K+ uptake, pH
homeostasis fails and intracellular pH decreases to lethal levels in acidic conditions.
Furthermore, it has been demonstrated that pH could affect K+ flux and regulate the
activity of K+ uptake systems in prokaryotes [Epstein, 2003]. Therefore, the effect of
pH on K+ transport in M. smegmatis needs to be explored in detail.
Although a connection between TrkA-dependent K+ transport and cell physi-
ology has been established in prokaryotes, its association with antibiotic tolerance
remains to be analyzed in detail. General alterations in antibiotic susceptibility are
frequently caused by permeability changes in the mycobacterial cell envelope due to
electrostatic perturbations [Nguyen and Thompson, 2006]. Our results suggest that
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the mechanism by which TrkA controls multidrug susceptibility is similarly based on
regulation of K+ transport, and its effect on pH homeostasis and membrane perme-
ability. K+ uptake is essential for the maintenance of a constant PMF through the
interconversion of membrane electrical potential to a pH gradient in Actinobacteria
[Follmann et al., 2009]. Impaired K+ uptake by inactivation of the Trk system or K+
insufficiency increase membrane potential in E. coli [Bakker and Mangerich, 1981].
In the yeast Schizosaccharomyces pombe, changes in membrane potential are associ-
ated with pleiotropic changes in the susceptibility to chemotherapeutic agents due to
impaired K+ uptake [Thornton et al., 2005]. Here, we demonstrate that the lack of
TrkA-dependent K+ uptake in M. smegmatis leads to increased membrane potential.
The hyperpolarized membrane of the M. smegmatis trkA mutant could attract and fa-
cilitate the penetration of positively charged antibiotic molecules into bacterial cells,
but might also reduce the diffusion of large hydrophobic drugs, such as rifampicin
or novobiocin. Additionally, both membrane potential and intracellular pH are key
components that control the activity of PMF-dependent multidrug eﬄux pumps in
prokaryotes [Su et al., 2006, Eicher et al., 2009]. Therefore, an impaired K+ uptake
could also indirectly modify the activity of eﬄux pumps in M. smegmatis and may
influence the susceptibility to antibiotics. However, our results showed a correlation
between the physicochemical properties of the antibiotics with their activities against
M. smegmatis, suggesting a direct effect of K+ uptake rates on bacterial permeability
to antimycobacterial agents.
The acquisition of rifampicin resistance in M. smegmatis by trkA inactivation en-
tails a conspicuous growth defect and a clear loss of fitness, probably due to the impact
on cell physiology of ionic imbalance and membrane hyperpolarization. In addition,
trkA mutants are attenuated for virulence in several bacterial pathogens, including
M. tuberculosis [Parra-Lopez et al., 1994, Chen et al., 2004, Rengarajan et al., 2005]
suggesting a low frequency of trkA (ceoB) mutations among rifampicin resistant M.
tuberculosis clinical isolates; however, the occurrence of different trkA mutations in
M. tuberculosis strains remains to be explored. Our results indicate that by modifying
cell permeability, alterations in ion transport promote a change in the M. smegma-
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tis susceptibility pattern to antibiotics. K+ supply might be an important element
in this effect; variations in K+ levels could influence antibiotic diffusion and pro-
duce changes in drug susceptibility. In addition to trkA, the M. smegmatis genome
contains two others genes, MSMEG 2769 (trkB) and MSMEG 1945 (ich), which
encode a putative K+ transporter (see below). Mycobacteria also encode another
main K+-uptake system, named Kdp, a P-type ATPase. Kdp is an inducible system
with high affinity for K+ and requires ATP hydrolysis to promote K+ uptake in E.
coli [Greie and Altendorf, 2007]. Furthermore, ABC components could also develop
a regulatory role in Trk-mediated K+ uptake [Harms et al., 2001]. As other proteins
involved in ion transport might also influence antibiotic effectiveness, it would be of
interest to explore the role of ion transporters in intrinsic resistance and the acquisi-
tion of drug resistance in mycobacteria. On the other hand, K+ uptake is inhibited by
some compounds with anti-mycobacterial activity, such as the riminophenazine clo-
fazimine [Steel et al., 1999]. Our data, nonetheless, indicate that the inhibition of K+
uptake could induce a complex pattern of phenotypes, including increased resistance
to anti-mycobacterial drugs such as rifampicin. Such collateral resistance should be
carefully considered when combined treatments are designed.
5.2.2 Ich
We found that the 4ich mutant need an additional amount of K+ to grow. Indeed,
it grew better when more K+ was added to the medium at different concentrations.
This result provides physiological evidences that the Ich protein may function as a
potassium transporter. Our study also suggested that the role of the Ich protein in
potassium transport relies on its structure which contains the TrkA-N domain having
a nucleotide-binding sequence previously identified as a flavin adenine dinucleotide-
binding motif.
While the mutants lacking of the ich gene poorly grew in normal MB medium,
their growth was restored by adding more K+. The fact that additional K+ are
required for the mutants lacking of ich to balance their growth suggests that the Ich
protein may play an important role in the maintenance of sufficient K+ concentration
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in the cells of M. smegmatis.
In general, ionic channels are very important in underpinning numerous funda-
mental physiological processes. Therefore, ionic channels are certainly considered
as a major class of drug targets [Clare, 2010]. In bacteria, this kind of proteins
plays an important role in antibiotic resistance. For instance, the K+ uptake sys-
tem Trk including TrkA was determined to be associated with general functions in
antibiotic resistance profile in many bacteria such as E. coli [Girgis et al., 2009] and
Pseudomonas aeruginosa [Lee et al., 2009].
Our experimental results showed the participation of the ich gene having a TrkA
domain in antibiotic resistance profile of M. smegmatis. On one hand, we found that
the deletion of the ich gene in M. smegmatis was associated with hypersusceptibility
to hydrophilic antibiotics (cationic agents) such as INH and aminoglycosides. Yet on
the other hand, it was also associated with the increasing resistance to many other
hydrophobic/lipophilic antibiotics such as rifampicin, novobiocin and floroquinolones.
In addition to the decrease of the susceptibility to rifampicin, the mutants lacking
of ich increase the susceptibility to INH. This result demonstrated the role of ich in
the protection of M. smegmatis from INH. Because the Ich protein has a TrkA-N
domain, the Ich protein can protect bacteria from INH based on those two previous
mechanisms described in the TrkA part (see above). Furthermore, the double mutant
with deletions of both genes trkA and ich showed higher susceptibility to INH. As
the 4trkA mutant of M. smegmatis was determined to increase its susceptibility to
INH in our previous work [Castaneda-G’arcia et al., 2011], we hypothesize that the
deficiency of both genes causes the increasing of susceptibility to INH.
An increase of susceptibility to ethionamide was observed in mutants lacking of
the ich gene and the double mutant with deletions of both genes ich and trkA. Ethion-
amide and INH have a similar structure and the mechanism of both drugs requires
the activation of prodrug [Johnsson et al., 1995]. Although there are significant dif-
ferences in their activation mechanisms, both of these drugs have a common target,
i.e. InhA. It has been determined that the alteration of NADH/NAD+ ratios is not
only related to the activation of INH as we have discussed above but also involved
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in the activation of ethionamide. Indeed, the change of the NADH/NAD+ ratios is
associated with inhibiting the binding of INH and ethionamide to their target InhA
[Vilcheze et al., 2005]. Interestingly, we did not see the increase of susceptibility to
ethionamide of the mutant lacking of trkA via identification of its MIC. Another
interesting result is that, the 4ich mutant is more susceptible to INH than 4trkA.
Therefore, we hypothesize that the change of NADH/NAD+ ratios maybe much larger
in 4ich than that in 4trkA. This hypothesis should be verified more carefully by ex-
perimental works in the future.
In the literature, it has been determined that the presence of K+ is necessary
for the maintenance of neutral internal pH in several well-known bacteria such as E.
coli [Kroll and Booth, 1981], Lactococcus lactis [Kashket and Barker, 1977] and also
Steptococcus mutans [Dashper and Reynolds, 1992]. Experiments about the growth
of bacteria at pH value ranging from 5 to 8 in the absence of K+ and at pH value 5.5
in the presence of K+ confirmed the importance of K+ under acidic conditions. An
increase of sensitivity to acidic conditions was observed with mutants without the ich
gene. Indeed, the mutants were growing with similar to growing level of wild-type
at alkaline and neutral pH, but their growth was significantly impaired at low pH
values. At pH 5.5, additional K+ was necessary to support the growths of mutants.
In the presence of sufficient K+ (100mM), the 4ich mutant almost reach the growth
level of wild-type. Interestingly, we found that the double mutant with deletions of
both genes ich and trkA had almost lost its capacity at low pH (5.5). Besides, when
the single mutants have recovered their growth with the additional K+, the growth
of double mutant was still very bad.
Our results demonstrate that the disruption of K+ transport by the loss of Ich
function impaired the capacity for pH homeostasis in M. smegmatis, and the intra-
cellular pH decreases significantly to lethal level in acidic conditions. Therefore, Ich
plays an important role in the growth at acidic conditions. Moreover, the internal
pH is also regulated by the other system such as the K+ eﬄux and the K+ uptake
systems. Particularly, our results together with the results of our previous work indi-
cated that both Ich and TrkA participated in the regulation of internal pH. However,
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the role of the ich gene in the regulation of internal pH is still unveiled and need more
efforts to understand it deeply.
We found that mutants with inactivation of Ich protein showed an increase of 4ψ
which were then decreased by the adding K+. The highest membrane potential was
observed in the double mutant lacking of two genes trkA and ich. Because both of
these genes involve in the regulation of membrane potential via the K+ transport, their
absence should cause the highest unbalance in the K+ transport. As a consequence,
it causes the highest difference between concentrations of K+ inside and outside the
cell. It is also a reason of the observation that the highest membrane potential was
obtained in double mutant cells.
The ionic imbalance and hyperpolirization may lower the growth of the mutants
with the ich deletion. Moreover, we suggested that the modification of membrane
permeability, the change in ionic transport of M. smegmatis take a crucial part in
antibiotic resistance profile. The supplement of K+ could be considered as an impor-
tant factor in this process. Indeed, the maintained K+ inside the cells may have an
effect in the penetration of antibiotics across the membrane and the change in K+
transport. Thus, it can cause alternations in antibiotic susceptibility. In this work,
we determined the function of the Ich protein as a putative K+ channel. Furthermore,
the genome of M. smegmatis also has other proteins taking part in the K+ transport
including the uptake the eﬄux systems. It would be interesting to study the role of
ionic transporters in the resistance development to antibiotics in mycobacteria. As
we have discussed above, the membrane potential and intracellular pH are important
factors which regulated the activity of the drug eﬄux pumps depending on PMF in
prokaryote [Su et al., 2006, Eicher et al., 2009]. Thus, the K+ transport could have
effects on the function of drug eﬄux pumps. The relation between the K+ transport
system, in particular the activity of the Ich protein, and the function of drug eﬄux
pumps should be carried in a future work to identify the molecular mechanisms of





1. Sublethal concentrations of eight antibiotics, including ampicillin, ceftazidime,
trimethoprim/sulfamethoxazole, imipenem, ciprofloxacin, trimethoprim, sulfamethox-
azole, and tetracycline, are able to stimulate mutagenesis of E. coli.
2. While most antibiotics have a slight effect with mild increase in mutagene-
sis, trimethoprim, sulfamethoxazole and the combination of trimethoprim plus
sulfamethoxazole produced the highest effect with highest increase in mutant
frequency for both rifampicin and fosfomycin resistance. In this case, both SOS
response and nucleotide imbalance might act synergistically to increase mutant
frequency.
3. Inactivation of recA abolishes the induction of mutagenesis produced by differ-
ent antibiotics. Thus, most mutagenesis induced by sublethal concentrations of
antibiotics depends on RecA activity.
4. The disruptions of trkA and ich result in the increase of rifampicin resistance
in M. smegmatis.
5. TrkA mediates K+ uptake, and it is essential for maintaining the growth of M.
smegmatis, its pH homeostasis and membrane potential.
6. The Ich protein is a putative K+ transporter which plays an important role
in the maintenance of sufficient K+ concentration in the cells of M. smegmatis.
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Similar to TrkA, Ich is essential for the growth at acidic conditions, it also takes
part in the regulation of membrane potential of bacteria.
7. TrkA takes an important part in regulation of antibiotic susceptibility. Deletion
of the trkA gene modifies M. smegmatis susceptibility to a wide variety of an-
tibiotics. Indeed, the M. smegmatis 4trkA mutant showed hypersusceptibility
to cationic agents, such as aminoglycosides, and increased resistance to large
hydrophobic antibiotics, including rifampicin, novobiocin and fluoroquinolones.
8. Inactivation of ich also causes the change of antibiotic resistance profile of M.
smegmatis, mutants lacking of ich, on one hand, become resistance to hydropho-
bic antibiotics such as novobiocin and rifampicin, and on the other hand, they
are more susceptible to hydrophilic antibiotics, such as isoniazid and aminogly-
cosides
9. TrkA and Ich are considered as general regulators of antibiotic susceptibility.
The change in antibiotic resistance profile of M. smegmatis in the absence of
the TrkA or Ich proteins is associated with membrane hyperpolarization.
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4-1 Effect of sublethal concentrations of antimicrobials on mutant fre-
quency. Fold changes in mutant frequency of the wild-type (wt) strain
ME12 (black bars) and its recA mutant derivative (grey bars) for ri-
fampicin resistance (RIFR) (a) and fosfomycin resistance (FOSR) (b),
after treatment with antibiotics. Data are relative to untreated controls
(no antibiotic). Only concentrations with the highest change in mu-
tant frequency are represented. The number in parentheses below the
antibiotic indicates the concentration relative to its MIC. Values are
the means of five experiments ±SD. Asterisks indicate that the fold
increases relative to the untreated strain are statistically significant
(P < 0.05), according to the MannWhitney U-test). AMP, ampicillin;
CAZ, ceftazidime; IPM, imipenem; CIP, ciprofloxacin; TMP, trimetho-
prim; SUL, sulfamethoxazole; SXT, trimethoprim/sulfamethoxazole;
CST, colistin; TET, tetracycline; GEN, gentamicin; CHL, chloram-
phenicol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
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4-2 Effects of antibiotics on the transcription of the recA::GFP fusion after
16 hours on solid surface. 100µl of an overnight culture were inoculated
into LB-soft agar (agar 0.7 %) and spread onto LB plates. Antibiotic-
containing filter disks were deposited onto the gelified agar, and plates
were visualized through a blue-light lamp after 16 hours of incubation
at 37oC. Induction is observed as a fluorescent band around the inhi-
bition halo produced by Amp, Caz, Cip, Tri, Sul and Tri/Sul. This
assay permits the exploration of the full range of antibiotic concentra-
tions for SOS induction without knowing the most effective.The disks
contain different amounts of antibiotic (g): Amp (500), Caz (10), Imi
(40), Fos (100), Cip (10), Tri (300), Sul (3,200), Tri/Sul (13.5/256),
Col (200), Tet (100), Gen (200), Rif (200) and Chl (300). Disks con-
taining no antibiotic and 10 g of mitomycin-C (Mito), a known inducer
of the SOS system, have been used as negative and positive controls,
respectively. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
4-3 Effects of antibiotics on cell morphology. Bacterial cultures were treated
for 4 hours as indicated in the Materials and Methods section. A: Effect
on the wild-type strain ME12. B: Effect on the ME12 recA derivative.
Bars at the right bottom of each image represent 10 µm. . . . . . . . 57
4-4 Analysis of the M. smegmatis trkA gene. (A) Vertical arrows indi-
cate the location of transposon insertion in each rifampin-resistant
mutant (number of base pair in the trkA gene)(top). Domain orga-
nization of the TrkA protein, showing the NAD(H)-binding motif se-
quence (bottom). (B) Alignment of TrkA sequences from M. smegma-
tis (MSMEG 2771), M. tuberculosis (Rv2691) and E. coli. Asterisks
indicate identical residues. . . . . . . . . . . . . . . . . . . . . . . . . 61
96
4-5 Survival (%) of M. smegmatis mc2 155 wild-type and the 4trkA mu-
tant under different concentrations of antibiotics. Percent of survivors
of the wild-type (black bars) and the 4trkA mutant (grey bars) to
rifampin (A), isoniazid (B), ciprofloxacin (C) and streptomycin (D)
are shown. Survivors were determined by plating serial dilutions on
Middlebrock 7H10 agar plates with the indicated antibiotic concen-
trations, and represented as the percent of surviving cells (viable cells
determined on antibiotic-containing plates divided by total viable cells
x100). The asterisks indicate lack of growth on plates with the indi-
cated antibiotic concentrations, representing in all cases a survival of
≤ 0.0001%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
4-6 Growth curves and K+ effect on growth of mc2 155 and its 4trkA
derivative. (A) Growth curves of M. smegmatis wild-type mc2 155
(closed circles) and its4trkA deletion mutant (open circles). (B) Effect
of K+ addition (10-200 mM KCl) on growth of mc2 155 (black bars)
and 4trkA (grey bars). The ability of high K+ concentrations to
restore growth of the 4trkA mutant was measured in cultures at mid-
exponential phase (12 h). Values, optical density at 600 nm, (OD600)
are mean±SD of three experiments. . . . . . . . . . . . . . . . . . . . 66
4-7 Growth curves and K+ effect on growth of mc2 155 and its 4trkA
derivative. (A) Growth curves of M. smegmatis wild-type mc2 155
(closed circles) and its4trkA deletion mutant (open circles). (B) Effect
of K+ addition (10-200 mM KCl) on growth of mc2 155 (black bars)
and 4trkA (grey bars). The ability of high K+ concentrations to
restore growth of the 4trkA mutant was measured in cultures at mid-
exponential phase (12 h). Values, optical density at 600 nm, (OD600)
are mean±SD of three experiments. . . . . . . . . . . . . . . . . . . . 68
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4-8 Membrane potential assay. (a) Exponentially growing cultures of M.
smegmatis wild-type mc2 155 (closed circles) and its 4trkA derivative
(open circles) were incubated with rhodamine 123. The curves, moni-
tored for 10 min, show the decrease in fluorescence emission produced
by intracellular quenching of the probe. . (b) Effect of K+ addition
(50-200 mM KCl) on membrane potential of mc2 155 and 4trkA. Cells
were pre-incubated for 30 minutes with increasing KCl concentrations
(50-200 mM KCl). Fluorescence decay was measured after 10 minutes
of incubation with rhodamine 123. Values show the mean ±SD. . . . 69
4-9 Location of transposon insertion. Vertical arrows indicate the location
of transposon insertion in a rifampin-resistant mutant (number of base
pair in the ich gene)(top). Domain organization of the Ich protein,
showing the TrkA-N domain (bottom). . . . . . . . . . . . . . . . . . 71
4-10 Viability (%) of M. smegmatis mc2 155 wild-type, 4ich and 4ich-
4trkA mutants under different concentrations of antibiotics. Percent-
age of viabilities of the wild-type (blue bars), 4ich (red bars) and
the 4ich-4trkA mutant (yellow bars) to rifampin (A), isoniazid (B),
ciprofloxacin (C) ) at the indicated antibiotic concentrations are shown. 74
4-11 Growth curves and K+ effect on the growth of the mc2 155, the 4ich
and the 4ich-4trkA mutants. (A) Growth curves of M. smegmatis
wild-type mc2 155 (blue colors),4ich (red colors) and4ich-4trkA(yellow
colors). (B) The effect of K+ addition (10-200 mM KCl) on the growth
of mc2 155 (blue bars), 4ich (red bars) and4ich-4trkA (yellow bars).
The ability of high K+ concentrations to restore growth of the mutants
was measured in cultures at mid-exponential phase (12 hours). Values,
optical density at 600 nm, (OD 600) mean ±SD. . . . . . . . . . . . . 76
98
4-12 Effect of extracellular pH on growth of the 4ich and the 4ich-4trkA
mutants. (A) Effect of pH (5.0 to 8.0) on the growth of mc2 155 (blue
bars), 4ich (red bars) and 4ich-4trkA (yellow bars) in Middlebrook
7H9 liquid medium (initial OD600 0.05). (B) Effect of K+ addition (10-
100 mM KCl) on the growth of mc2 155 (blue bars), 4ich (red bars)
and4ich-4trkA (yellow bars) at pH 5.5. Optical density (OD600) was
measured after 12 hours incubation at 37oC. Values show the mean±SD 77
4-13 Membrane potential assay. Exponentially growing cultures (without
KCl) of M. smegmatis mc2 155 (blue bars), 4ich(red bars) and 4ich-
4trkA (yellow bars) were incubated with rhodamine 123. The curves
show the decrease in fluorescence emission produced by intracellular
quenching of the probe. Effect of K+ addition (100 mM KCl) on the
membrane potential of mc2 155,4ich and4ich-4trkA. Cells were pre-
incubated for 30 min with increasing KCl concentrations. Fluorescence
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4.1 Minimal inhibitory concentrations (µg/ml) of the antimicrobials used
in this study against the wild-type strain ME12 and its recA-derivative.]:
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4.3 MIC of the main groups of antimycobacterial agents for M. smegmatis
wild-type mc2 155 and the 4trkA mutant. Antibiotics are ordered
by solubility values from hydrophobic to hydrophilic. ]: predicted
solubility according to Drugbank (http://www.drugbank.ca) . . . . . 63
4.4 Fitness of M. smegmatis mc2 155 and its 4trkA-derivative during the
logarithmic growth phase. Strains were grown in mixed cultures until
late logarithmic phase (three independent experiments). The number
of divisions and the doubling time of each strain were obtained from
CFU counts on drug-containing and drug-free plates. The 4trkA mu-
tant fitness was measured as the ratio of the number of generations of
the rifampin-resistant strain relative to those of the wild type strain. . 67
101
4.5 MIC of the main group of antimycobacterial agents for M. smegmatis
wild-type mc2 155, the 4ich, the 4ich-4trkA mutants and the com-
plementation strain of the 4ich. Antibiotics are ordered by solubility
values from hydrophobic to hydrophilic. . . . . . . . . . . . . . . . . . 73
4.6 The growth rates and doubling time of the mc2 155, the 4ich and the
4ich-4trkA mutants. The growth rate was estimated as the maximum
slope of the natural logarithm of optical densities versus time . . . . . 75
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